{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:09:50Z","timestamp":1794809390063,"version":"4.9.1"},"reference-count":640,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170974"],"award-info":[{"award-number":["82170974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","award":["2023QYJC038"],"award-info":[{"award-number":["2023QYJC038"]}],"id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune evasion represents a significant challenge in oncology. It allows tumors to evade immune surveillance and destruction, thereby complicating therapeutic interventions and contributing to suboptimal patient outcomes. This review addresses the critical need to understand how cancers evade immune surveillance. It aims to provide a comprehensive overview of strategies of tumors to escape immune detection by examining tumor-induced immune suppression, immune checkpoint regulation, and genetic and epigenetic influences. Moreover, it explores the dynamic role of the tumor microenvironment (TME) in fostering immune resistance and highlights the impact of metabolic reprogramming on immune suppression. Additionally, this review focuses on how tumor heterogeneity influences immune evasion and discusses the limitations of current immunotherapies. The role of key signaling pathways, including programmed cell death protein 1\/programmed cell death ligand 1 (PD-1\/PD-L1), cytotoxic T-lymphocyte\u2013associated antigen 4 (CTLA-4), transforming growth factor-\u03b2 (TGF-\u03b2), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB), and cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS\u2013STING) is analyzed to elucidate their contributions to immune escape. Emphasizing the complexities of immune evasion, this review underscores the importance of personalized approaches and the integration of multi-omics data to combat therapeutic resistance. Furthermore, it discusses novel and emerging therapeutic strategies, such as bispecific antibodies, oncolytic viruses, and nanotechnology-driven immunotherapies, showcasing innovative avenues in cancer treatment. The significance of this review lies in its potential to guide future research and innovations in immunotherapy, ultimately improving patient outcomes and advancing our understanding of cancer immunology.<\/jats:p>","DOI":"10.1038\/s41392-025-02280-1","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:03:05Z","timestamp":1753916585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":430,"title":["Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-7216","authenticated-orcid":false,"given":"Muhammad","family":"Tufail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can-Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2280_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40610-023-00157-2","volume":"10","author":"A Caner","year":"2024","unstructured":"Caner, A. Immune escape mechanism of cancer. Curr. Mol. Biol. Rep. 10, 9\u201319 (2024).","journal-title":"Curr. Mol. Biol. Rep."},{"key":"2280_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202107540","volume":"31","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Immune cycle-based strategies for cancer immunotherapy. Adv. Funct. Mater. 31, 2107540 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"2280_CR3","doi-asserted-by":"crossref","unstructured":"Dutta, S. et al. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology 12, 218 (2023).","DOI":"10.3390\/biology12020218"},{"key":"2280_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1634\/theoncologist.2015-0282","volume":"21","author":"JL Messerschmidt","year":"2016","unstructured":"Messerschmidt, J. L., Prendergast, G. C. & Messerschmidt, G. L. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances. Oncologist 21, 233\u2013243 (2016).","journal-title":"Oncologist"},{"key":"2280_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymthe.2024.01.012","volume":"32","author":"P O\u2019Connell","year":"2024","unstructured":"O\u2019Connell, P. Uncovering mechanisms underlying complement-mediated cancer immune evasion. Mol. Ther. 32, 277\u2013278 (2024).","journal-title":"Mol. Ther."},{"key":"2280_CR6","doi-asserted-by":"publisher","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim, S. K. & Cho, S. W. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front. Pharmacol. 13, 868695 (2022).","journal-title":"Front. Pharmacol."},{"key":"2280_CR7","doi-asserted-by":"crossref","unstructured":"Martinez-Castillo, M. et al. An overview of the immune modulatory properties of long non-coding RNAs and their potential use as therapeutic targets in cancer. Noncoding RNA 9, 70 (2023).","DOI":"10.3390\/ncrna9060070"},{"key":"2280_CR8","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s10238-023-01104-2","volume":"23","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. Immunology and immunotherapy in gastric cancer. Clin. Exp. Med. 23, 3189\u20133204 (2023).","journal-title":"Clin. Exp. Med."},{"key":"2280_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten, T. F. et al. Immunology and immunotherapy of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 20, 349\u2013365 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2280_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41416-020-01160-5","volume":"124","author":"SC Edwards","year":"2021","unstructured":"Edwards, S. C., Hoevenaar, W. H. M. & Coffelt, S. B. Emerging immunotherapies for metastasis. Br. J. Cancer 124, 37\u201348 (2021).","journal-title":"Br. J. Cancer"},{"key":"2280_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).","journal-title":"Mol. Cancer"},{"key":"2280_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04257-8","volume":"12","author":"K Riegel","year":"2021","unstructured":"Riegel, K. et al. ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. Cell Death Dis. 12, 969 (2021).","journal-title":"Cell Death Dis."},{"key":"2280_CR13","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1538-7445.AM2025-1212","volume":"85","author":"KM O\u2019Donnell","year":"2025","unstructured":"O\u2019Donnell, K. M. et al. Disruption of G\u03b1s\/cAMP-mediated acid sensing by breast tumor cells blunts tumor-induced immune suppression and decreases bone metastases by enhancing cytotoxic T cell function. Cancer Res. 85, 1212\u20131212 (2025).","journal-title":"Cancer Res."},{"key":"2280_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/intimm\/dxy042","volume":"30","author":"K Shimizu","year":"2018","unstructured":"Shimizu, K. et al. Immune suppression and reversal of the suppressive tumor microenvironment. Int. Immunol. 30, 445\u2013455 (2018).","journal-title":"Int. Immunol."},{"key":"2280_CR15","doi-asserted-by":"crossref","unstructured":"Rogovskii, V. Tumor-produced immune regulatory factors as a therapeutic target in cancer treatment. Front. Immunol. 15, 1416458 (2024).","DOI":"10.3389\/fimmu.2024.1416458"},{"key":"2280_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1158\/2326-6066.CIR-17-0117","volume":"5","author":"D Gurusamy","year":"2017","unstructured":"Gurusamy, D., Clever, D., Eil, R. & Restifo, N. P. Novel \u201celements\u201d of immune suppression within the tumor microenvironment. Cancer Immunol. Res. 5, 426\u2013433 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"2280_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","volume":"21","author":"D Briukhovetska","year":"2021","unstructured":"Briukhovetska, D. et al. Interleukins in cancer: from biology to therapy. Nat. Rev. Cancer 21, 481\u2013499 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2280_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel, H. L. & Mercurio, A. M. VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871\u2013882 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2280_CR20","first-page":"7042","volume":"62","author":"E Barbera-Guillem","year":"2002","unstructured":"Barbera-Guillem, E. et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 62, 7042\u20137049 (2002).","journal-title":"Cancer Res."},{"key":"2280_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s13402-023-00830-9","volume":"46","author":"B Pan","year":"2023","unstructured":"Pan, B. et al. TGF-\u03b2-p-STAT1-LAIR2 axis has a \u201cself-rescue\u201d role for exhausted CD8+ T cells in hepatocellular carcinoma. Cell Oncol. 46, 1625\u20131644 (2023).","journal-title":"Cell Oncol."},{"key":"2280_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","journal-title":"Cancer Cell"},{"key":"2280_CR23","doi-asserted-by":"publisher","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","volume":"9","author":"S Viel","year":"2016","unstructured":"Viel, S. et al. TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19\u2013ra19 (2016).","journal-title":"Sci. Signal."},{"key":"2280_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jconrel.2024.02.008","volume":"367","author":"SH Choi","year":"2024","unstructured":"Choi, S. H. et al. Nano-chemical priming strategy to enhance TGF-\u03b2 resistance and anti-tumor activity of natural killer cells. J. Control Release 367, 768\u2013778 (2024).","journal-title":"J. Control Release"},{"key":"2280_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41423-023-01036-7","volume":"20","author":"J Wang","year":"2023","unstructured":"Wang, J., Zhao, X. & Wan, Y. Y. Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology. Cell Mol. Immunol. 20, 1002\u20131022 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2280_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jmcb\/mjr033","volume":"4","author":"DQ Tran","year":"2012","unstructured":"Tran, D. Q. TGF-\u03b2: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell Biol. 4, 29\u201337 (2012).","journal-title":"J. Mol. Cell Biol."},{"key":"2280_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","volume":"72","author":"KM Sullivan","year":"2023","unstructured":"Sullivan, K. M. et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut 72, 325 (2023).","journal-title":"Gut"},{"key":"2280_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","volume":"2","author":"M Oft","year":"2014","unstructured":"Oft, M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol. Res. 2, 194\u2013199 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR29","doi-asserted-by":"crossref","unstructured":"Littwitz-Salomon, E., Malyshkina, A., Schimmer, S. & Dittmer, U. The cytotoxic activity of natural killer cells is suppressed by IL-10+ regulatory T cells during acute retroviral infection. Front. Immunol. 9, 1947 (2018).","DOI":"10.3389\/fimmu.2018.01947"},{"key":"2280_CR30","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746\u2013756 (2021).","journal-title":"Nat. Immunol."},{"key":"2280_CR31","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/s41375-021-01217-1","volume":"35","author":"JR Rivas","year":"2021","unstructured":"Rivas, J. R. et al. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia 35, 3188\u20133200 (2021).","journal-title":"Leukemia"},{"key":"2280_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00262-006-0234-7","volume":"56","author":"K Mimura","year":"2007","unstructured":"Mimura, K. et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol. Immunother. 56, 761\u2013770 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"2280_CR33","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.4049\/jimmunol.1601116","volume":"197","author":"NAE Oussa","year":"2016","unstructured":"Oussa, N. A. E. et al. VEGF requires the receptor NRP-1 to inhibit lipopolysaccharide-dependent dendritic cell maturation. J. Immunol. 197, 3927\u20133935 (2016).","journal-title":"J. Immunol."},{"key":"2280_CR34","doi-asserted-by":"crossref","unstructured":"Aguiar, R. B. d. & Moraes, J. Z. d. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front. Immunol. 10, 1023 (2019).","DOI":"10.3389\/fimmu.2019.01023"},{"key":"2280_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01714-0","volume":"22","author":"M Iglesias-Escudero","year":"2023","unstructured":"Iglesias-Escudero, M., Arias-Gonz\u00e1lez, N. & Mart\u00ednez-C\u00e1ceres, E. Regulatory cells and the effect of cancer immunotherapy. Mol. Cancer 22, 26 (2023).","journal-title":"Mol. Cancer"},{"key":"2280_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J. Transl. Med. 22, 293 (2024).","journal-title":"J. Transl. Med."},{"key":"2280_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth, C. et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120, 16\u201325 (2019).","journal-title":"Br. J. Cancer"},{"key":"2280_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2280_CR39","doi-asserted-by":"crossref","unstructured":"Li, X. et al. Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy. Front. Immunol. 12, 754196 (2021).","DOI":"10.3389\/fimmu.2021.754196"},{"key":"2280_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07122-6","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis. 15, 775 (2024).","journal-title":"Cell Death Dis."},{"key":"2280_CR41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12195-020-00652-x","volume":"13","author":"R Sangsuwan","year":"2020","unstructured":"Sangsuwan, R. et al. Lactate exposure promotes immunosuppressive phenotypes in innate immune cells. Cell Mol. Bioeng. 13, 541\u2013557 (2020).","journal-title":"Cell Mol. Bioeng."},{"key":"2280_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2020.12.021","volume":"500","author":"C Hayes","year":"2021","unstructured":"Hayes, C., Donohoe, C. L., Davern, M. & Donlon, N. E. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment. Cancer Lett. 500, 75\u201386 (2021).","journal-title":"Cancer Lett."},{"key":"2280_CR43","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer, K. et al. Inhibitory effect of tumor cell\u2013derived lactic acid on human T cells. Blood 109, 3812\u20133819 (2007).","journal-title":"Blood"},{"key":"2280_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17756-7","volume":"11","author":"H Wu","year":"2020","unstructured":"Wu, H. et al. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat. Commun. 11, 4113 (2020).","journal-title":"Nat. Commun."},{"key":"2280_CR45","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto, A. et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 72, 2746\u20132756 (2012).","journal-title":"Cancer Res."},{"key":"2280_CR46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas, S. et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76, 1381\u20131390 (2016).","journal-title":"Cancer Res."},{"key":"2280_CR47","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2326-6066.CIR-18-0657","volume":"7","author":"SC Chafe","year":"2019","unstructured":"Chafe, S. C. et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol. Res. 7, 1064\u20131078 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR48","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/ijc.30646","volume":"140","author":"J P\u00f6tzl","year":"2017","unstructured":"P\u00f6tzl, J. et al. Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-\u03b3 and induces NK cell-dependent lymphoma control without other immunotherapies. Int. J. Cancer 140, 2125\u20132133 (2017).","journal-title":"Int. J. Cancer"},{"key":"2280_CR49","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559\u2013563 (2014).","journal-title":"Nature"},{"key":"2280_CR50","doi-asserted-by":"crossref","unstructured":"Lin, Y. et al. Crosstalk between lactic acid and immune regulation and its value in the diagnosis and treatment of liver failure. Open Life Sci. 18, 20220636 (2023).","DOI":"10.1515\/biol-2022-0636"},{"key":"2280_CR51","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1073\/pnas.1505924112","volume":"112","author":"L Cao","year":"2015","unstructured":"Cao, L. et al. pH-dependent recognition of apoptotic and necrotic cells by the human dendritic cell receptor DEC205. Proc. Natl. Acad. Sci. USA 112, 7237\u20137242 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2280_CR52","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/s41556-024-01503-x","volume":"26","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Ammonia-induced lysosomal and mitochondrial damage causes cell death of effector CD8+ T cells. Nat. Cell Biol. 26, 1892\u20131902 (2024).","journal-title":"Nat. Cell Biol."},{"key":"2280_CR53","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","volume":"12","author":"C Ghosh","year":"2021","unstructured":"Ghosh, C., Luong, G. & Sun, Y. A snapshot of the PD-1\/PD-L1 pathway. J. Cancer 12, 2735\u20132746 (2021).","journal-title":"J. Cancer"},{"key":"2280_CR54","doi-asserted-by":"crossref","unstructured":"Mej\u00eda-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D. & Rodr\u00edguez-Garc\u00eda, J. A. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. Front. Immunol. 14, 1298571 (2023).","DOI":"10.3389\/fimmu.2023.1298571"},{"key":"2280_CR55","doi-asserted-by":"crossref","unstructured":"Ouyang, P. et al. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. Front. Immunol. 15, 1344272 (2024).","DOI":"10.3389\/fimmu.2024.1344272"},{"key":"2280_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika, K. J. et al. Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non\u2013small cell lung cancer. Cancer Res. 76, 227\u2013238 (2016).","journal-title":"Cancer Res."},{"key":"2280_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin, X. et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol. Cancer 23, 108 (2024).","journal-title":"Mol. Cancer"},{"key":"2280_CR58","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko, K. et al. IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501\u20131509 (2015).","journal-title":"Br. J. Cancer"},{"key":"2280_CR59","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2280_CR60","doi-asserted-by":"crossref","unstructured":"Ziogas, D. C. et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers 15, 2718 (2023).","DOI":"10.3390\/cancers15102718"},{"key":"2280_CR61","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke, J. J. et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat. Med. 29, 2814\u20132824 (2023).","journal-title":"Nat. Med."},{"key":"2280_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","volume":"39","author":"CM Fares","year":"2019","unstructured":"Fares, C. M. et al. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?. Am. Soc. Clin. Oncol. Educ. Book 39, 147\u2013164 (2019).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2280_CR63","doi-asserted-by":"publisher","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","volume":"6","author":"G Shayan","year":"2017","unstructured":"Shayan, G. et al. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology 6, e1261779 (2017).","journal-title":"Oncoimmunology"},{"key":"2280_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).","journal-title":"Nat. Commun."},{"key":"2280_CR65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","volume":"38","author":"NA Manieri","year":"2017","unstructured":"Manieri, N. A., Chiang, E. Y. & Grogan, J. L. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 38, 20\u201328 (2017).","journal-title":"Trends Immunol."},{"key":"2280_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48\u201357 (2009).","journal-title":"Nat. Immunol."},{"key":"2280_CR67","doi-asserted-by":"crossref","unstructured":"Meng, F. et al. Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes. Front. Oncol. 10, 1595 (2020).","DOI":"10.3389\/fonc.2020.01595"},{"key":"2280_CR68","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor, W. A. et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39, 1342\u20131360.e1314 (2021).","journal-title":"Cancer Cell"},{"key":"2280_CR69","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bbrc.2020.12.013","volume":"534","author":"D Han","year":"2021","unstructured":"Han, D. et al. A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity. Biochem. Biophys. Res. Commun. 534, 134\u2013140 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2280_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.828319","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGB-A1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. Front. Immunol. 13, 828319 (2022).","journal-title":"Front. Immunol."},{"key":"2280_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116162","volume":"223","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy. Biochem. Pharm. 223, 116162 (2024).","journal-title":"Biochem. Pharm."},{"key":"2280_CR72","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","volume":"11","author":"E Schaafsma","year":"2023","unstructured":"Schaafsma, E. et al. VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance. Cancer Immunol. Res. 11, 38\u201355 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR73","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1038\/s12276-024-01336-6","volume":"56","author":"RJ Zhang","year":"2024","unstructured":"Zhang, R. J. & Kim, T. K. VISTA-mediated immune evasion in cancer. Exp. Mol. Med. 56, 2348\u20132356 (2024).","journal-title":"Exp. Mol. Med."},{"key":"2280_CR74","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/2326-6066.CIR-18-0507","volume":"7","author":"J Deng","year":"2019","unstructured":"Deng, J. et al. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol. Res. 7, 1079\u20131090 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR75","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2217\/imt-2021-0338","volume":"14","author":"O Akdo\u011fan","year":"2022","unstructured":"Akdo\u011fan, O. et al. Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. Immunotherapy 14, 1121\u20131131 (2022).","journal-title":"Immunotherapy"},{"key":"2280_CR76","doi-asserted-by":"publisher","first-page":"1086102","DOI":"10.3389\/fimmu.2023.1086102","volume":"14","author":"AS Martin","year":"2023","unstructured":"Martin, A. S. et al. VISTA expression and patient selection for immune-based anticancer therapy. Front. Immunol. 14, 1086102 (2023).","journal-title":"Front. Immunol."},{"key":"2280_CR77","doi-asserted-by":"crossref","unstructured":"Zong, L. et al. High VISTA expression correlates with a favorable prognosis in patients with colorectal cancer. J. Immunother. 44, 22\u201328 (2021).","DOI":"10.1097\/CJI.0000000000000343"},{"key":"2280_CR78","doi-asserted-by":"crossref","unstructured":"Cao, X. et al. VISTA expression on immune cells correlates with favorable prognosis in patients with triple-negative breast cancer. Front. Oncol. 10, 583966 (2021).","DOI":"10.3389\/fonc.2020.583966"},{"key":"2280_CR79","doi-asserted-by":"publisher","first-page":"e1469594","DOI":"10.1080\/2162402X.2018.1469594","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. OncoImmunology 7, e1469594 (2018).","journal-title":"OncoImmunology"},{"key":"2280_CR80","doi-asserted-by":"publisher","first-page":"654960","DOI":"10.3389\/fimmu.2021.654960","volume":"12","author":"Z Ning","year":"2021","unstructured":"Ning, Z., Liu, K. & Xiong, H. Roles of BTLA in immunity and immune disorders. Front. Immunol. 12, 654960 (2021).","journal-title":"Front. Immunol."},{"key":"2280_CR81","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00262-023-03435-1","volume":"72","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde, C. et al. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. Cancer Immunol. Immunother. 72, 2529\u20132539 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"2280_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6545921","volume":"2020","author":"L Karabon","year":"2020","unstructured":"Karabon, L. et al. Abnormal expression of BTLA and CTLA-4 immune checkpoint molecules in chronic lymphocytic leukemia patients. J. Immunol. Res. 2020, 6545921 (2020).","journal-title":"J. Immunol. Res."},{"key":"2280_CR83","doi-asserted-by":"crossref","unstructured":"Sun, W. Z. et al. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors. J. Immunother. Cancer 11, e006694 (2023).","DOI":"10.1136\/jitc-2023-006694"},{"key":"2280_CR84","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.7150\/ijbs.60782","volume":"17","author":"X Jia","year":"2021","unstructured":"Jia, X. et al. CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy. Int. J. Biol. Sci. 17, 3281\u20133287 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2280_CR85","doi-asserted-by":"publisher","first-page":"1027235","DOI":"10.3389\/fimmu.2022.1027235","volume":"13","author":"J Son","year":"2022","unstructured":"Son, J. et al. Inhibition of the CD47-SIRP\u03b1 axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data. Front. Immunol. 13, 1027235 (2022).","journal-title":"Front. Immunol."},{"key":"2280_CR86","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.7150\/thno.40860","volume":"10","author":"T Hu","year":"2020","unstructured":"Hu, T. et al. Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics 10, 4056\u20134072 (2020).","journal-title":"Theranostics"},{"key":"2280_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150066","volume":"720","author":"C-H Chuang","year":"2024","unstructured":"Chuang, C.-H. et al. CD47-mediated immune evasion in early-stage lung cancer progression. Biochem. Biophys. Res. Commun. 720, 150066 (2024).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2280_CR88","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cam4.478","volume":"4","author":"K Yoshida","year":"2015","unstructured":"Yoshida, K. et al. CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 4, 1322\u20131333 (2015).","journal-title":"Cancer Med."},{"key":"2280_CR89","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2280_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108813","volume":"108","author":"J Lao","year":"2022","unstructured":"Lao, J. et al. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer. Int. Immunopharmacol. 108, 108813 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"2280_CR91","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","volume":"43","author":"B Thapa","year":"2024","unstructured":"Thapa, B. et al. OX40\/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 43, 1001\u20131013 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"2280_CR92","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1084\/jem.20071341","volume":"205","author":"S Piconese","year":"2008","unstructured":"Piconese, S., Valzasina, B. & Colombo, M. P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825\u2013839 (2008).","journal-title":"J. Exp. Med."},{"key":"2280_CR93","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fonc.2015.00034","volume":"5","author":"SN Linch","year":"2015","unstructured":"Linch, S. N., McNamara, M. J. & Redmond, W. L. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front. Oncol. 5, 34 (2015).","journal-title":"Front. Oncol."},{"key":"2280_CR94","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","volume":"159","author":"Y Ma","year":"2020","unstructured":"Ma, Y. et al. Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer. Gastroenterology 159, 306\u2013319 (2020).","journal-title":"Gastroenterology"},{"key":"2280_CR95","doi-asserted-by":"crossref","unstructured":"Melero, I. et al. CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary. Cancer Discov. 13, 552\u2013569 (2023).","DOI":"10.1158\/2159-8290.CD-22-1029"},{"key":"2280_CR96","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0043-1764419","volume":"18","author":"F Bin-Alee","year":"2024","unstructured":"Bin-Alee, F. et al. High 4-1BB expression in PBMCs and tumor infiltrating lymphocytes (TILs) in patients with head and neck squamous cell carcinoma. Eur. J. Dent. 18, 236\u2013242 (2024).","journal-title":"Eur. J. Dent."},{"key":"2280_CR97","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.immuni.2018.09.014","volume":"49","author":"SL Buchan","year":"2018","unstructured":"Buchan, S. L. et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity 49, 958\u2013970.e957 (2018).","journal-title":"Immunity"},{"key":"2280_CR98","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/jcm12041355","volume":"12","author":"M Andreescu","year":"2023","unstructured":"Andreescu, M., Fr\u00eencu, F., Plotogea, M. & Mehedin\u021bu, C. Recurrent abortion and the involvement of killer-cell immunoglobulin-like receptor (KIR) genes, activated T cells, NK abnormalities, and cytokine profiles. J. Clin. Med. 12, 1355 (2023).","journal-title":"J. Clin. Med."},{"key":"2280_CR99","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1034\/j.1600-065X.2001.1810119.x","volume":"181","author":"EO Long","year":"2001","unstructured":"Long, E. O. et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol. Rev. 181, 223\u2013233 (2001).","journal-title":"Immunol. Rev."},{"key":"2280_CR100","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt, H. E. et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678\u2013686 (2014).","journal-title":"Blood"},{"key":"2280_CR101","doi-asserted-by":"crossref","unstructured":"Liu, H. et al. Lirilumab and avelumab enhance anti-HPV+ cervical cancer activity of natural killer cells via Vav1-dependent NF-\u03baB disinhibition. Front. Oncol. 12, 747482 (2022).","DOI":"10.3389\/fonc.2022.747482"},{"key":"2280_CR102","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1182\/blood.V130.Suppl_1.889.889","volume":"130","author":"N Vey","year":"2017","unstructured":"Vey, N. et al. Randomized phase 2 trial of lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with Acute Myeloid Leukemia (AML): results of the Effikir trial. Blood 130, 889\u2013889 (2017).","journal-title":"Blood"},{"key":"2280_CR103","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4049\/jimmunol.182.2.829","volume":"182","author":"A Saez-Borderias","year":"2009","unstructured":"Saez-Borderias, A. et al. IL-12-dependent inducible expression of the CD94\/NKG2A inhibitory receptor regulates CD94\/NKG2C+ NK cell function. J. Immunol. 182, 829\u2013836 (2009).","journal-title":"J. Immunol."},{"key":"2280_CR104","doi-asserted-by":"crossref","unstructured":"Vietzen, H. et al. Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas. Front. Immunol. 14, 1183788 (2023).","DOI":"10.3389\/fimmu.2023.1183788"},{"key":"2280_CR105","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272\u2013287.e279 (2023).","journal-title":"Cancer Cell"},{"key":"2280_CR106","doi-asserted-by":"crossref","unstructured":"de Dios, O. et al. NKG2C\/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. J. Immunother. Cancer. 12, e009210 (2024).","DOI":"10.1136\/jitc-2024-009210"},{"key":"2280_CR107","doi-asserted-by":"crossref","unstructured":"Baghban, R. et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18, 59, 1-19 (2020).","DOI":"10.1186\/s12964-020-0530-4"},{"key":"2280_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-022-00894-z","volume":"30","author":"B Cheng","year":"2023","unstructured":"Cheng, B., Yu, Q. & Wang, W. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. J. Biomed. Sci. 30, 1 (2023).","journal-title":"J. Biomed. Sci."},{"key":"2280_CR109","doi-asserted-by":"crossref","unstructured":"Basak, U. et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front. Immunol. 14, 1295257 (2023).","DOI":"10.3389\/fimmu.2023.1295257"},{"key":"2280_CR110","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan, Y., Yu, Y., Wang, X. & Zhang, T. Tumor-Associated Macrophages In Tumor Immunity. Front. Immunol. 11, 583084 (2020).","journal-title":"Front. Immunol."},{"key":"2280_CR111","doi-asserted-by":"crossref","unstructured":"Boutilier, A. J. & Elsawa, S. F. Macrophage Polarization States In The Tumor Microenvironment. Int. J. Mol. Sci. 22, 6995 (2021).","DOI":"10.3390\/ijms22136995"},{"key":"2280_CR112","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin, Y., Xu, J. & Lan, H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12, 76 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis. Oncol. 8, 31 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2280_CR114","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang, R., Kang, T. & Chen, S. The role of tumor-associated macrophages in tumor immune evasion. J. Cancer Res. Clin. Oncol. 150, 238 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2280_CR115","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","volume":"23","author":"X Yuan","year":"2024","unstructured":"Yuan, X. et al. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat. Rev. Drug Discov. 23, 175\u2013200 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2280_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad, A. et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 21, 62 (2021).","journal-title":"Cancer Cell Int."},{"key":"2280_CR117","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.4251\/wjgo.v13.i11.1725","volume":"13","author":"Z Deng","year":"2021","unstructured":"Deng, Z. et al. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World J. Gastrointest. Oncol. 13, 1725\u20131740 (2021).","journal-title":"World J. Gastrointest. Oncol."},{"key":"2280_CR118","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","volume":"11","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. HIF-1\u03b1 signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 11, 234\u2013251 (2024).","journal-title":"Genes Dis."},{"key":"2280_CR119","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","volume":"27","author":"K Xu","year":"2019","unstructured":"Xu, K. et al. Hypoxia induces drug resistance in colorectal cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 feedback loop. Mol. Ther. 27, 1810\u20131824 (2019).","journal-title":"Mol. Ther."},{"key":"2280_CR120","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/sj.onc.1210008","volume":"26","author":"M Kilic","year":"2007","unstructured":"Kilic, M., Kasperczyk, H., Fulda, S. & Debatin, K. M. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26, 2027\u20132038 (2007).","journal-title":"Oncogene"},{"key":"2280_CR121","doi-asserted-by":"crossref","unstructured":"Vitale, M. & Parodi, M. Blocking HIF to enhance NK cells: hints for new anti-tumor therapeutic strategies? Vaccines. 9, 1144 (2021).","DOI":"10.3390\/vaccines9101144"},{"key":"2280_CR122","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s44318-024-00319-7","volume":"44","author":"H Estephan","year":"2025","unstructured":"Estephan, H. et al. Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation. EMBO J. 44, 903\u2013922 (2025). 922.","journal-title":"EMBO J."},{"key":"2280_CR123","doi-asserted-by":"crossref","unstructured":"Awad, R. M. et al. Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression. Front. Immunol. 9, 1977 (2018).","DOI":"10.3389\/fimmu.2018.01977"},{"key":"2280_CR124","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner, E. N. & Rathmell, J. C. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41, 421\u2013433 (2023).","journal-title":"Cancer Cell"},{"key":"2280_CR125","doi-asserted-by":"publisher","first-page":"1353787","DOI":"10.3389\/fimmu.2024.1353787","volume":"15","author":"A Nicolini","year":"2024","unstructured":"Nicolini, A. & Ferrari, P. Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy. Front. Immunol. 15, 1353787 (2024).","journal-title":"Front. Immunol."},{"key":"2280_CR126","doi-asserted-by":"crossref","unstructured":"Li, A. M. & Ye, J. Deciphering the Warburg effect: metabolic reprogramming, epigenetic remodeling, and cell dedifferentiation. Annu. Rev. Cancer Biol. 8 (2024).","DOI":"10.1146\/annurev-cancerbio-062822-120857"},{"key":"2280_CR127","doi-asserted-by":"crossref","unstructured":"Enr\u00edquez, J. A. & Mittelbrunn, M. Warburg effect reshapes tumor immunogenicity. Cancer Res. 84, 2043\u20132045 (2024).","DOI":"10.1158\/0008-5472.CAN-24-1304"},{"key":"2280_CR128","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1158\/0008-5472.CAN-12-3696","volume":"73","author":"I Kareva","year":"2013","unstructured":"Kareva, I. & Hahnfeldt, P. The emerging \u201challmarks\u201d of metabolic reprogramming and immune evasion: distinct or linked?. Cancer Res. 73, 2737\u20132742 (2013).","journal-title":"Cancer Res."},{"key":"2280_CR129","doi-asserted-by":"crossref","unstructured":"Zhang, X. et al. The role of tumor metabolic reprogramming in tumor immunity. Int. J. Mol. Sci. 24, 17422 (2023).","DOI":"10.3390\/ijms242417422"},{"key":"2280_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20, 28 (2021).","journal-title":"Mol. Cancer"},{"key":"2280_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-016-0110-9","volume":"5","author":"C Herbel","year":"2016","unstructured":"Herbel, C. et al. Clinical significance of T cell metabolic reprogramming in cancer. Clin. Transl. Med. 5, 29 (2016).","journal-title":"Clin. Transl. Med."},{"key":"2280_CR132","first-page":"20190001","volume":"5","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Immune response in glioma\u2019s microenvironment. Innov. Surg. Sci. 5, 20190001 (2020).","journal-title":"Innov. Surg. Sci."},{"key":"2280_CR133","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imr.12978","volume":"302","author":"R Mhaidly","year":"2021","unstructured":"Mhaidly, R. & Mechta-Grigoriou, F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol. Rev. 302, 259\u2013272 (2021).","journal-title":"Immunol. Rev."},{"key":"2280_CR134","doi-asserted-by":"crossref","unstructured":"Marshall, L. A. et al. Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4. J. Immunother. Cancer. 8, e000764 (2020).","DOI":"10.1136\/jitc-2020-000764"},{"key":"2280_CR135","doi-asserted-by":"publisher","first-page":"1078.9","DOI":"10.1096\/fasebj.22.1_supplement.1078.9","volume":"22","author":"AW Mailloux","year":"2008","unstructured":"Mailloux, A. W. & Young, M. R. I. Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) produce CCL22 which selectively recruits regulatory T-cells (Tregs) to the tumor microenvironment. FASEB J. 22, 1078.9\u20131078.9 (2008).","journal-title":"FASEB J."},{"key":"2280_CR136","doi-asserted-by":"crossref","unstructured":"Korbecki, J. et al. Hypoxia alters the expression of CC chemokines and CC chemokine receptors in a tumor-a literature review. Int. J. Mol. Sci. 21, 5647 (2020).","DOI":"10.3390\/ijms21165647"},{"key":"2280_CR137","doi-asserted-by":"crossref","unstructured":"Korbecki, J. et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int. J. Mol. Sci. 21, 8412 (2020).","DOI":"10.3390\/ijms21218412"},{"key":"2280_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01165-x","volume":"19","author":"H Yang","year":"2020","unstructured":"Yang, H. et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol. Cancer 19, 41 (2020).","journal-title":"Mol. Cancer"},{"key":"2280_CR139","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41418-019-0460-0","volume":"27","author":"C Liu","year":"2020","unstructured":"Liu, C. et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65\/STAT3-CSN5-PD-L1 pathway. Cell Death Differ. 27, 1765\u20131781 (2020).","journal-title":"Cell Death Differ."},{"key":"2280_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"2280_CR141","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fonc.2020.00397","volume":"10","author":"S Brassart-Pasco","year":"2020","unstructured":"Brassart-Pasco, S. et al. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front. Oncol. 10, 397 (2020).","journal-title":"Front. Oncol."},{"key":"2280_CR142","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1172\/JCI127515","volume":"130","author":"NS Sharma","year":"2020","unstructured":"Sharma, N. S. et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J. Clin. Invest. 130, 451\u2013465 (2020).","journal-title":"J. Clin. Invest."},{"key":"2280_CR143","doi-asserted-by":"crossref","unstructured":"Lv, D. et al. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment. Front. Immunol. 15, 1340702 (2024).","DOI":"10.3389\/fimmu.2024.1340702"},{"key":"2280_CR144","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","volume":"100","author":"E Hessmann","year":"2020","unstructured":"Hessmann, E. et al. Microenvironmental determinants of pancreatic cancer. Physiol. Rev. 100, 1707\u20131751 (2020).","journal-title":"Physiol. Rev."},{"key":"2280_CR145","doi-asserted-by":"crossref","unstructured":"Palladino, S. et al. Development of a hyaluronic acid-collagen bioink for shear-induced fibers and cells alignment. Biomed. Mater. 18, 065017 (2023).","DOI":"10.1088\/1748-605X\/acfd77"},{"key":"2280_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20, 131 (2021).","journal-title":"Mol. Cancer"},{"key":"2280_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1113378","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang, C. et al. CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy?. Front. Pharmacol. 14, 1113378 (2023).","journal-title":"Front. Pharmacol."},{"key":"2280_CR148","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/s41416-024-02639-1","volume":"130","author":"M Akai","year":"2024","unstructured":"Akai, M. et al. Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity. Br. J. Cancer 130, 1647\u20131658 (2024).","journal-title":"Br. J. Cancer"},{"key":"2280_CR149","doi-asserted-by":"crossref","unstructured":"Wright, K. et al. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers 15, 1899 (2023).","DOI":"10.3390\/cancers15061899"},{"key":"2280_CR150","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"G-Q Zhu","year":"2023","unstructured":"Zhu, G.-Q. et al. CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 9, 25 (2023).","journal-title":"Cell Discov."},{"key":"2280_CR151","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y. et al. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 29, 3044\u20133060 (2022).","journal-title":"Curr. Oncol."},{"key":"2280_CR152","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.2147\/JHC.S492582","volume":"11","author":"Y Nong","year":"2024","unstructured":"Nong, Y. et al. Oxymatrine inhibits PD-L1 by downregulating IFN-\u03b3 to promote ferroptosis and enhance anti-PD-L1 efficacy in liver cancer. J. Hepatocell. Carcinoma 11, 2427\u20132440 (2024).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"2280_CR153","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal, A. et al. Cancer immune escape: the role of antigen presentation machinery. J. Cancer Res. Clin. Oncol. 149, 8131\u20138141 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2280_CR154","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2280_CR155","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.it.2024.01.009","volume":"45","author":"J Wang","year":"2024","unstructured":"Wang, J., Lu, Q., Chen, X. & Aifantis, I. Targeting MHC-I inhibitory pathways for cancer immunotherapy. Trends Immunol. 45, 177\u2013187 (2024).","journal-title":"Trends Immunol."},{"key":"2280_CR156","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","volume":"566","author":"D Han","year":"2019","unstructured":"Han, D. et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"2280_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35710-7","volume":"14","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat. Commun. 14, 265 (2023).","journal-title":"Nat. Commun."},{"key":"2280_CR158","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-22-0815","volume":"11","author":"K Kawase","year":"2023","unstructured":"Kawase, K. et al. High expression of MHC class I overcomes cancer immunotherapy resistance due to IFN\u03b3 signaling pathway defects. Cancer Immunol. Res. 11, 895\u2013908 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR159","doi-asserted-by":"crossref","unstructured":"Johnson, D. B. et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement. JCI Insight 3, e120360 (2018).","DOI":"10.1172\/jci.insight.120360"},{"key":"2280_CR160","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","volume":"105","author":"P Leone","year":"2013","unstructured":"Leone, P. et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl. Cancer Inst. 105, 1172\u20131187 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"2280_CR161","doi-asserted-by":"crossref","unstructured":"Mpakali, A. & Stratikos, E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers 13, 134 (2021).","DOI":"10.3390\/cancers13010134"},{"key":"2280_CR162","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/gcc.20441","volume":"46","author":"AM Mehta","year":"2007","unstructured":"Mehta, A. M. et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 46, 577\u2013586 (2007).","journal-title":"Genes Chromosomes Cancer"},{"key":"2280_CR163","doi-asserted-by":"crossref","unstructured":"Massa, C., Wang, Y., Marr, N. & Seliger, B. Interferons and resistance mechanisms in tumors and pathogen-driven diseases\u2014focus on the major histocompatibility complex (MHC) antigen processing pathway. Int. J. Mol. Sci. 24, 6736 (2023).","DOI":"10.3390\/ijms24076736"},{"key":"2280_CR164","doi-asserted-by":"crossref","unstructured":"Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol. 12, 636568 (2021).","DOI":"10.3389\/fimmu.2021.636568"},{"key":"2280_CR165","doi-asserted-by":"publisher","first-page":"384","DOI":"10.37349\/ei.2023.00108","volume":"3","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty, S. et al. Immune evasion by cancer stem cells ensures tumor initiation and failure of immunotherapy. Explor. Immunol. 3, 384\u2013405 (2023).","journal-title":"Explor. Immunol."},{"key":"2280_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","volume":"1284","author":"MD Vesely","year":"2013","unstructured":"Vesely, M. D. & Schreiber, R. D. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. 1284, 1\u20135 (2013).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2280_CR167","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","volume":"94","author":"Y Liu","year":"2016","unstructured":"Liu, Y. & Cao, X. Immunosuppressive cells in tumor immune escape and metastasis. J. Mol. Med. 94, 509\u2013522 (2016).","journal-title":"J. Mol. Med."},{"key":"2280_CR168","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"2280_CR169","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0165-2478(94)00243-K","volume":"45","author":"MM Simon","year":"1995","unstructured":"Simon, M. M. et al. The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmenting\/co-stimulatory signals for the activation of CD4+ and CD8+ T cells. Immunol. Lett. 45, 137\u2013142 (1995).","journal-title":"Immunol. Lett."},{"key":"2280_CR170","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/intimm\/10.5.619","volume":"10","author":"N Pardigon","year":"1998","unstructured":"Pardigon, N. et al. Role of co-stimulation in CD8+ T cell activation. Int. Immunol. 10, 619\u2013630 (1998).","journal-title":"Int. Immunol."},{"key":"2280_CR171","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3389\/fimmu.2017.01447","volume":"8","author":"SC Shissler","year":"2017","unstructured":"Shissler, S. C., Lee, M. S. & Webb, T. J. Mixed signals: co-stimulation in invariant natural killer T cell-mediated cancer immunotherapy. Front. Immunol. 8, 1447 (2017).","journal-title":"Front. Immunol."},{"key":"2280_CR172","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00124743-200008000-00012","volume":"6","author":"LH Sigal","year":"2000","unstructured":"Sigal, L. H. Molecular biology and immunology for clinicians, 12: T-cell co-stimulatory molecules. J. Clin. Rheumatol. 6, 225\u2013227 (2000).","journal-title":"J. Clin. Rheumatol."},{"key":"2280_CR173","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","volume":"43","author":"W Yang","year":"2024","unstructured":"Yang, W. et al. T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. J. Exp. Clin. Cancer Res. 43, 38 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR174","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fcell.2020.00017","volume":"8","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. T cell dysfunction and exhaustion in cancer. Front. Cell Dev. Biol. 8, 17 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"2280_CR175","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."},{"key":"2280_CR176","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175\u20132186 (2010).","journal-title":"J. Exp. Med."},{"key":"2280_CR177","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917\u2013927 (2012).","journal-title":"Cancer Res."},{"key":"2280_CR178","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki, J. et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 107, 7875\u20137880 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2280_CR179","doi-asserted-by":"publisher","first-page":"775101","DOI":"10.3389\/fimmu.2021.775101","volume":"12","author":"SKR Noonepalle","year":"2021","unstructured":"Noonepalle, S. K. R., Karabon, L., Chiappinelli, K. B. & Villagra, A. Editorial: Genetic and epigenetic control of immune responses. Front. Immunol. 12, 775101 (2021).","journal-title":"Front. Immunol."},{"key":"2280_CR180","doi-asserted-by":"crossref","unstructured":"Matassa, D. S. et al. TRAP1 regulation of cancer metabolism: dual role as oncogene or tumor suppressor. Genes 9, 195 (2018).","DOI":"10.3390\/genes9040195"},{"key":"2280_CR181","doi-asserted-by":"publisher","first-page":"e2522","DOI":"10.1038\/cddis.2016.400","volume":"7","author":"MR Amoroso","year":"2016","unstructured":"Amoroso, M. R. et al. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial\u2013mesenchymal transition. Cell Death Dis. 7, e2522 (2016).","journal-title":"Cell Death Dis."},{"key":"2280_CR182","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2012-10-461988","volume":"121","author":"F Santoro","year":"2013","unstructured":"Santoro, F. et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121, 3459\u20133468 (2013).","journal-title":"Blood"},{"key":"2280_CR183","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.7150\/thno.45971","volume":"10","author":"F Du","year":"2020","unstructured":"Du, F. et al. KRAS mutation-responsive miR-139-5p inhibits colorectal cancer progression and is repressed by Wnt signaling. Theranostics 10, 7335\u20137350 (2020).","journal-title":"Theranostics"},{"key":"2280_CR184","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","volume":"6","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct. Target. Ther. 6, 144 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2280_CR185","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1053\/j.gastro.2013.01.071","volume":"144","author":"MP di Magliano","year":"2013","unstructured":"di Magliano, M. P. & Logsdon, C. D. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144, 1220\u20131229 (2013).","journal-title":"Gastroenterology"},{"key":"2280_CR186","doi-asserted-by":"crossref","unstructured":"Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother. Cancer. 10, e003402 (2022).","DOI":"10.1136\/jitc-2021-003402"},{"key":"2280_CR187","doi-asserted-by":"crossref","unstructured":"Hu, H. et al. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. J. Clin. Invest. 133 (2023).","DOI":"10.1172\/JCI153470"},{"key":"2280_CR188","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","volume":"42","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 42, 828\u2013847 (2022).","journal-title":"Cancer Commun."},{"key":"2280_CR189","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/2159-8290.CD-20-1543","volume":"11","author":"N Pore","year":"2021","unstructured":"Pore, N. et al. Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non\u2013small cell lung cancer and is reversed by STAT3 knockdown. Cancer Discov. 11, 2828\u20132845 (2021).","journal-title":"Cancer Discov."},{"key":"2280_CR190","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Liu, D. & Li, L. PD-1\/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10, 727\u2013742 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"2280_CR191","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati, A. V. R., Vadlamudi, R. K. & Curiel, T. J. Programmed death ligand 1 signals in cancer cells. Nat. Rev. Cancer 22, 174\u2013189 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2280_CR192","doi-asserted-by":"crossref","unstructured":"Nishida, N. Role of oncogenic pathways on the cancer immunosuppressive microenvironment and its clinical implications in hepatocellular carcinoma. Cancers 13, 3666 (2021).","DOI":"10.3390\/cancers13153666"},{"key":"2280_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou, S. et al. Targeting STAT3 in cancer immunotherapy. Mol. Cancer 19, 145 (2020).","journal-title":"Mol. Cancer"},{"key":"2280_CR194","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-024-00796-z","volume":"5","author":"G Efe","year":"2024","unstructured":"Efe, G., Rustgi, A. K. & Prives, C. p53 at the crossroads of tumor immunity. Nat. Cancer 5, 983\u2013995 (2024).","journal-title":"Nat. Cancer"},{"key":"2280_CR195","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-024-01566-1","volume":"17","author":"D Chai","year":"2024","unstructured":"Chai, D. et al. Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. J. Hematol. Oncol. 17, 45 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR196","doi-asserted-by":"crossref","unstructured":"Fusco, N. et al. PTEN alterations and their role in cancer management: are we making headway on precision medicine? Genes 11, 719 (2020).","DOI":"10.3390\/genes11070719"},{"key":"2280_CR197","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1172\/JCI121277","volume":"129","author":"L Yehia","year":"2019","unstructured":"Yehia, L., Ngeow, J. & Eng, C. PTEN-opathies: from biological insights to evidence-based precision medicine. J. Clin. Invest. 129, 452\u2013464 (2019).","journal-title":"J. Clin. Invest."},{"key":"2280_CR198","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao, J. & Yan, Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer 6, 580\u2013592 (2020).","journal-title":"Trends Cancer"},{"key":"2280_CR199","doi-asserted-by":"crossref","unstructured":"McClellan, B. L. et al. Impact of epigenetic reprogramming on antitumor immune responses in glioma. J. Clin. Invest. 133 (2023).","DOI":"10.1172\/JCI163450"},{"key":"2280_CR200","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1158\/0008-5472.CAN-20-0524","volume":"80","author":"B Koss","year":"2020","unstructured":"Koss, B. et al. Epigenetic control of Cdkn2a.Arf protects tumor-infiltrating lymphocytes from metabolic exhaustion. Cancer Res. 80, 4707\u20134719 (2020).","journal-title":"Cancer Res."},{"key":"2280_CR201","first-page":"1","volume":"7","author":"SA Abiola","year":"2024","unstructured":"Abiola, S. A. et al. Epigenetic modulation in breast cancer: from mechanisms to therapeutic interventions. Int. J. Oncol. 7, 1\u201313 (2024).","journal-title":"Int. J. Oncol."},{"key":"2280_CR202","doi-asserted-by":"crossref","unstructured":"Heydari, Z. et al. Alteration in DNA methylation patterns: epigenetic signatures in gastrointestinal cancers. Eur. J. Pharmacol. 176563 (2024).","DOI":"10.1016\/j.ejphar.2024.176563"},{"key":"2280_CR203","doi-asserted-by":"crossref","unstructured":"Zhang, J., Tian, Z., Qin, C. & Momeni, M. R. The effects of exercise on epigenetic modifications: focus on DNA methylation, histone modifications and non-coding RNAs. Human Cell 37, 1\u201317 (2024).","DOI":"10.1007\/s13577-024-01057-y"},{"key":"2280_CR204","doi-asserted-by":"publisher","first-page":"101821","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida, H. Q. et al. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl. Oncol. 39, 101821 (2024).","journal-title":"Transl. Oncol."},{"key":"2280_CR205","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.551","volume":"5","author":"S Qin","year":"2024","unstructured":"Qin, S. et al. New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication. MedComm 5, e551 (2024).","journal-title":"MedComm"},{"key":"2280_CR206","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3727\/096504014X13983417587320","volume":"21","author":"Y Tao","year":"2013","unstructured":"Tao, Y. et al. Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice. Oncol. Res.21, 307\u2013316 (2013).","journal-title":"Oncol. Res."},{"key":"2280_CR207","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01698-8","volume":"16","author":"JE Tovar Perez","year":"2024","unstructured":"Tovar Perez, J. E. et al. Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception. Clin. Epigenetics 16, 83 (2024).","journal-title":"Clin. Epigenetics"},{"key":"2280_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung, H. et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat. Commun. 10, 4278 (2019).","journal-title":"Nat. Commun."},{"key":"2280_CR209","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-94-007-4525-4_13","volume":"61","author":"JL Miller","year":"2013","unstructured":"Miller, J. L. & Grant, P. A. The role of DNA methylation and histone modifications in transcriptional regulation in humans. Subcell. Biochem. 61, 289\u2013317 (2013).","journal-title":"Subcell. Biochem."},{"key":"2280_CR210","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia, J. E. & Campbell, R. M. Histone modifications and cancer. Cold Spring Harb. Perspect. Biol. 8, a019521 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2280_CR211","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao, Z. & Shilatifard, A. Epigenetic modifications of histones in cancer. Genome Biol. 20, 245 (2019).","journal-title":"Genome Biol."},{"key":"2280_CR212","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg, D. et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 20, 854\u2013867 (2017).","journal-title":"Cell Rep."},{"key":"2280_CR213","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin, G. K. et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 595, 309\u2013314 (2021).","journal-title":"Nature"},{"key":"2280_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00413-7","volume":"11","author":"LH Chi","year":"2022","unstructured":"Chi, L. H. et al. MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. Oncogenesis 11, 38 (2022).","journal-title":"Oncogenesis"},{"key":"2280_CR215","doi-asserted-by":"crossref","unstructured":"Zhou, H., Jia, W., Lu, L. & Han, R. MicroRNAs with multiple targets of immune checkpoints, as a potential sensitizer for immune checkpoint inhibitors in breast cancer treatment. Cancers 15, 824 (2023).","DOI":"10.3390\/cancers15030824"},{"key":"2280_CR216","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00280-020-04168-z","volume":"86","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer. Cancer Chemother. Pharmacol. 86, 761\u2013772 (2020).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2280_CR217","doi-asserted-by":"crossref","unstructured":"Cabello, P. et al. miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cancers 15, 2138 (2023).","DOI":"10.3390\/cancers15072138"},{"key":"2280_CR218","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15129","volume":"8","author":"R Jiang","year":"2017","unstructured":"Jiang, R. et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat. Commun. 8, 15129 (2017).","journal-title":"Nat. Commun."},{"key":"2280_CR219","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41590-018-0207-y","volume":"19","author":"D Huang","year":"2018","unstructured":"Huang, D. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat. Immunol. 19, 1112\u20131125 (2018).","journal-title":"Nat. Immunol."},{"key":"2280_CR220","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.2147\/JIR.S460730","volume":"17","author":"W Li","year":"2024","unstructured":"Li, W., Zhang, H., You, Z. & Guo, B. LncRNAs in immune and stromal cells remodel phenotype of cancer cell and tumor microenvironment. J. Inflamm. Res. 17, 3173\u20133185 (2024).","journal-title":"J. Inflamm. Res."},{"key":"2280_CR221","doi-asserted-by":"publisher","first-page":"e004666","DOI":"10.1136\/jitc-2022-004666","volume":"10","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization. J. Immunother. Cancer 10, e004666 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2280_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05609-2","volume":"14","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1\u2013TINCR-USP20-PD-L1 axis. Cell Death Dis. 14, 76 (2023).","journal-title":"Cell Death Dis."},{"key":"2280_CR223","doi-asserted-by":"crossref","unstructured":"Wang, F. et al. cRNAsp12 web server for the prediction of circular RNA secondary structures and stabilities. Int. J. Mol. Sci. 24 3822 (2023).","DOI":"10.3390\/ijms24043822"},{"key":"2280_CR224","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/15476286.2023.2272468","volume":"20","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Circular RNAs: biology and clinical significance of breast cancer. RNA Biol. 20, 859\u2013874 (2023).","journal-title":"RNA Biol."},{"key":"2280_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06389-5","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng, L. et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 15, 3 (2024).","journal-title":"Cell Death Dis."},{"key":"2280_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2230-9","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. circRNA-002178 act as a ceRNA to promote PDL1\/PD1 expression in lung adenocarcinoma. Cell Death Dis. 11, 32 (2020).","journal-title":"Cell Death Dis."},{"key":"2280_CR227","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10616-023-00577-z","volume":"75","author":"L Fan","year":"2023","unstructured":"Fan, L., Xu, G. & Zeng, X. M2 macrophage-derived extracellular vesicles augment immune evasion and development of colorectal cancer via a circRNA_CCDC66\/microRNA-342-3p\/metadherin axis. Cytotechnology 75, 293\u2013308 (2023).","journal-title":"Cytotechnology"},{"key":"2280_CR228","doi-asserted-by":"publisher","first-page":"110868","DOI":"10.1016\/j.intimp.2023.110868","volume":"124","author":"A Du","year":"2023","unstructured":"Du, A., Yang, Q., Sun, X. & Zhao, Q. Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression. Int. Immunopharmacol. 124, 110868 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2280_CR229","doi-asserted-by":"publisher","first-page":"e004029","DOI":"10.1136\/jitc-2021-004029","volume":"10","author":"H Li","year":"2022","unstructured":"Li, H. et al. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J. Immunother. Cancer 10, e004029 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2280_CR230","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41417-021-00382-w","volume":"30","author":"Y He","year":"2023","unstructured":"He, Y. et al. circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation. Cancer Gene Ther. 30, 559\u2013566 (2023).","journal-title":"Cancer Gene Ther."},{"key":"2280_CR231","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.ymthe.2020.07.001","volume":"28","author":"Q Chen","year":"2020","unstructured":"Chen, Q. et al. Circular RNA circSnx5 controls immunogenicity of dendritic cells through the miR-544\/SOCS1 axis and PU.1 activity regulation. Mol. Ther. 28, 2503\u20132518 (2020).","journal-title":"Mol. Ther."},{"key":"2280_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01213-6","volume":"19","author":"X-Y Huang","year":"2020","unstructured":"Huang, X.-Y. et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis. Mol. Cancer 19, 92 (2020).","journal-title":"Mol. Cancer"},{"key":"2280_CR233","first-page":"9","volume":"7","author":"DL Chen","year":"2024","unstructured":"Chen, D. L., Chen, N., Sheng, H. & Zhang, D. S. Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer. Cancer Drug Resist. 7, 9 (2024).","journal-title":"Cancer Drug Resist."},{"key":"2280_CR234","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01759-1","volume":"22","author":"Z Hu","year":"2023","unstructured":"Hu, Z. et al. Exosome-derived circCCAR1 promotes CD8\u2009+\u2009T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol. Cancer 22, 55 (2023).","journal-title":"Mol. Cancer"},{"key":"2280_CR235","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01586-w","volume":"21","author":"L-X Zhang","year":"2022","unstructured":"Zhang, L.-X. et al. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p\/CARM1 axis. Mol. Cancer 21, 110 (2022).","journal-title":"Mol. Cancer"},{"key":"2280_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1111-2","volume":"18","author":"P-F Zhang","year":"2019","unstructured":"Zhang, P.-F. et al. Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol. Cancer 18, 179 (2019).","journal-title":"Mol. Cancer"},{"key":"2280_CR237","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01448-x","volume":"20","author":"S-W Chen","year":"2021","unstructured":"Chen, S.-W. et al. Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934\/SHP2 axis in NSCLC. Mol. Cancer 20, 144 (2021).","journal-title":"Mol. Cancer"},{"key":"2280_CR238","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01475-8","volume":"20","author":"D-L Chen","year":"2021","unstructured":"Chen, D.-L. et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol. Cancer 20, 166 (2021).","journal-title":"Mol. Cancer"},{"key":"2280_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01146-3","volume":"14","author":"M Golkaram","year":"2022","unstructured":"Golkaram, M. et al. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. Genome Med. 14, 143 (2022).","journal-title":"Genome Med."},{"key":"2280_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0600-4","volume":"16","author":"PR Prasetyanti","year":"2017","unstructured":"Prasetyanti, P. R. & Medema, J. P. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer 16, 41 (2017).","journal-title":"Mol. Cancer"},{"key":"2280_CR241","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","volume":"98","author":"YCS Ram\u00f3n","year":"2020","unstructured":"Ram\u00f3n, Y. C. S. et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J. Mol. Med. 98, 161\u2013177 (2020).","journal-title":"J. Mol. Med."},{"key":"2280_CR242","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.xcrm.2023.101055","volume":"4","author":"P Cunnea","year":"2023","unstructured":"Cunnea, P. et al. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes. Cell Rep. Med. 4, 101055 (2023).","journal-title":"Cell Rep. Med."},{"key":"2280_CR243","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04336-8","volume":"21","author":"D Zhang","year":"2023","unstructured":"Zhang, D. et al. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma. J. Transl. Med. 21, 489 (2023).","journal-title":"J. Transl. Med."},{"key":"2280_CR244","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41416-024-02684-w","volume":"131","author":"K Chen","year":"2024","unstructured":"Chen, K., Shuen, T. W. H. & Chow, P. K. H. The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. Br. J. Cancer 131, 420\u2013429 (2024).","journal-title":"Br. J. Cancer"},{"key":"2280_CR245","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0900-y","volume":"15","author":"DR Caswell","year":"2017","unstructured":"Caswell, D. R. & Swanton, C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 15, 133 (2017).","journal-title":"BMC Med."},{"key":"2280_CR246","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","volume":"11","author":"Q Jia","year":"2022","unstructured":"Jia, Q. et al. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp. Hematol. Oncol. 11, 24 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"2280_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101855","volume":"40","author":"Q Zhu","year":"2024","unstructured":"Zhu, Q. et al. Heterogeneity of computational pathomic signature predicts drug resistance and intra-tumor heterogeneity of ovarian cancer. Transl. Oncol. 40, 101855 (2024).","journal-title":"Transl. Oncol."},{"key":"2280_CR248","doi-asserted-by":"crossref","unstructured":"Martinez-Bosch, N., Vinaixa, J. & Navarro, P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers 10, 6 (2018).","DOI":"10.3390\/cancers10010006"},{"key":"2280_CR249","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2217\/imt.11.112","volume":"3","author":"J Leibovici","year":"2011","unstructured":"Leibovici, J., Itzhaki, O., Huszar, M. & Sinai, J. Targeting the tumor microenvironment by immunotherapy: part 2. Immunotherapy 3, 1385\u20131408 (2011).","journal-title":"Immunotherapy"},{"key":"2280_CR250","doi-asserted-by":"crossref","unstructured":"Schaller, J. & Agudo, J. Metastatic colonization: escaping immune surveillance. Cancers 12, 3385 (2020).","DOI":"10.3390\/cancers12113385"},{"key":"2280_CR251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653358","volume":"12","author":"E Lin","year":"2021","unstructured":"Lin, E. et al. Roles of the dynamic tumor immune microenvironment in the individualized treatment of advanced clear cell renal cell carcinoma. Front. Immunol. 12, 653358 (2021).","journal-title":"Front. Immunol."},{"key":"2280_CR252","doi-asserted-by":"crossref","unstructured":"Rodriguez, B. L. et al. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1\/CTLA-4 immunotherapy resistance. Front. Immunol. 14, 1161869 (2023).","DOI":"10.3389\/fimmu.2023.1161869"},{"key":"2280_CR253","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302268","volume":"13","author":"HY Mu","year":"2024","unstructured":"Mu, H. Y. et al. Ex vivo evaluation of combination immunotherapy using tumor-microenvironment-on-chip. Adv. Health. Mater. 13, e2302268 (2024).","journal-title":"Adv. Health. Mater."},{"key":"2280_CR254","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"Z-F Lim","year":"2019","unstructured":"Lim, Z.-F. & Ma, P. C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J. Hematol. Oncol. 12, 134 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR255","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2280_CR256","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"2280_CR257","doi-asserted-by":"crossref","unstructured":"Yuan, Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harb. Perspect. Med. 6, a026583 (2016).","DOI":"10.1101\/cshperspect.a026583"},{"key":"2280_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47541-9","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in hepatocellular carcinoma. Nat. Commun. 15, 3169 (2024).","journal-title":"Nat. Commun."},{"key":"2280_CR259","first-page":"222","volume":"6","author":"M Tanaka","year":"2025","unstructured":"Tanaka, M. et al. Tumor cell heterogeneity drives spatial organization of the intratumoral immune response. J. Exp. Med. 6, 222 (2025).","journal-title":"J. Exp. Med."},{"key":"2280_CR260","doi-asserted-by":"crossref","unstructured":"Ganguly, A., Mukherjee, S. & Spada, S. Editorial: Spatial immune cell heterogeneity in the tumor microenvironment. Front. Immunol. 15, 1377532 (2024).","DOI":"10.3389\/fimmu.2024.1377532"},{"key":"2280_CR261","doi-asserted-by":"crossref","unstructured":"Sobti, A. et al. Exploring spatial heterogeneity of immune cells in nasopharyngeal cancer. Cancers 15, 2165 (2023).","DOI":"10.3390\/cancers15072165"},{"key":"2280_CR262","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10585-021-10091-1","volume":"39","author":"W Ma","year":"2022","unstructured":"Ma, W., Pham, B. & Li, T. Cancer neoantigens as potential targets for immunotherapy. Clin. Exp. Metastasis 39, 51\u201360 (2022).","journal-title":"Clin. Exp. Metastasis"},{"key":"2280_CR263","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jcmm.17643","volume":"27","author":"D-J Zhang","year":"2023","unstructured":"Zhang, D.-J. et al. Circ_0000052\/miR-382-3p axis induces PD-L1 expression and regulates cell proliferation and immune evasion in head and neck squamous cell carcinoma. J. Cell Mol. Med. 27, 113\u2013126 (2023).","journal-title":"J. Cell Mol. Med."},{"key":"2280_CR264","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. NRIR promotes immune escape in hepatocellular cancer by regulating IFN\u03b3-induced PD-L1 expression. J. Adv. Res. (2025).","DOI":"10.1016\/j.jare.2025.02.034"},{"key":"2280_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115378","volume":"208","author":"R-H Yang","year":"2023","unstructured":"Yang, R.-H. et al. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma. Biochem. Pharmacol. 208, 115378 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"2280_CR266","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides, M. et al. Hallmarks of resistance to immune-checkpoint inhibitors. Cancer Immunol. Res. 10, 372\u2013383 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR267","doi-asserted-by":"crossref","unstructured":"Lee, J. & Kim, E. H. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy. Front. Oncol. 13, 1233376 (2023).","DOI":"10.3389\/fonc.2023.1233376"},{"key":"2280_CR268","doi-asserted-by":"crossref","unstructured":"Zhou, K., Li, S., Zhao, Y. & Cheng, K. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer. Front. Immunol. 14, 1127071 (2023).","DOI":"10.3389\/fimmu.2023.1127071"},{"key":"2280_CR269","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/curroncol31010001","volume":"31","author":"CH Coschi","year":"2024","unstructured":"Coschi, C. H. & Juergens, R. A. Overcoming resistance mechanisms to immune checkpoint inhibitors: leveraging the anti-tumor immune response. Curr. Oncol. 31, 1\u201323 (2024).","journal-title":"Curr. Oncol."},{"key":"2280_CR270","doi-asserted-by":"publisher","first-page":"568931","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson, K., Cross, N., Jordan-Mahy, N. & Leyland, R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front. Immunol. 11, 568931 (2020).","journal-title":"Front. Immunol."},{"key":"2280_CR271","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front. Pharmacol. 12, 731798 (2021).","DOI":"10.3389\/fphar.2021.731798"},{"key":"2280_CR272","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","volume":"10","author":"W Qin","year":"2019","unstructured":"Qin, W. et al. The Diverse Function of PD-1\/PD-L Pathway Beyond Cancer. Front Immunol. 10, 2298 (2019).","journal-title":"Front Immunol."},{"key":"2280_CR273","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi, M. et al. Regulation of PD-L1 expression in the tumor microenvironment. J. Hematol. Oncol. 14, 10 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR274","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1007\/s00432-022-04458-4","volume":"149","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma. J. Cancer Res. Clin. Oncol. 149, 5127\u20135138 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2280_CR275","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00109-024-02444-6","volume":"102","author":"A Salminen","year":"2024","unstructured":"Salminen, A. The role of the immunosuppressive PD-1\/PD-L1 checkpoint pathway in the aging process and age-related diseases. J. Mol. Med. 102, 733\u2013750 (2024).","journal-title":"J. Mol. Med."},{"key":"2280_CR276","first-page":"19","volume":"10","author":"S Amirhosein","year":"2024","unstructured":"Amirhosein, S. et al. The role of PD-1\/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review. J. Cancer Metastasis Treat. 10, 19 (2024).","journal-title":"J. Cancer Metastasis Treat."},{"key":"2280_CR277","doi-asserted-by":"crossref","unstructured":"Song, M.-K., Park, B.-B. & Uhm, J. Understanding immune evasion and therapeutic targeting associated with PD-1\/PD-L1 pathway in diffuse large B-cell lymphoma. Int. J. Mol. Sci. 20 1326 (2019).","DOI":"10.3390\/ijms20061326"},{"key":"2280_CR278","doi-asserted-by":"crossref","unstructured":"Kim, S.-B., Hwang, S., Cha, J.-Y. & Lee, H.-J. Programmed death ligand 1 regulatory crosstalk with ubiquitination and deubiquitination: implications in cancer immunotherapy. Int. J. Mol. Sci. 25 2939 (2024).","DOI":"10.3390\/ijms25052939"},{"key":"2280_CR279","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","volume":"12","author":"N Zhang","year":"2024","unstructured":"Zhang, N. et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark. Res. 12, 26 (2024).","journal-title":"Biomark. Res."},{"key":"2280_CR280","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00384-x","volume":"7","author":"Z Hui","year":"2023","unstructured":"Hui, Z. et al. PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells. NPJ Precis. Oncol. 7, 48 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"2280_CR281","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 15, 14 (2023).","journal-title":"Genome Med."},{"key":"2280_CR282","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05057-4","volume":"13","author":"Z Hui","year":"2022","unstructured":"Hui, Z. et al. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). Cell Death Dis. 13, 607 (2022).","journal-title":"Cell Death Dis."},{"key":"2280_CR283","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"J-Y Sun","year":"2020","unstructured":"Sun, J.-Y. et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark. Res. 8, 35 (2020).","journal-title":"Biomark. Res."},{"key":"2280_CR284","doi-asserted-by":"crossref","unstructured":"Lei, Q. et al. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front. Cell Dev. Biol. 8, 672 (2020).","DOI":"10.3389\/fcell.2020.00672"},{"key":"2280_CR285","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30143-8","volume":"13","author":"P John","year":"2022","unstructured":"John, P. et al. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. Nat. Commun. 13, 2506 (2022).","journal-title":"Nat. Commun."},{"key":"2280_CR286","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan, B., Halliday, N. & Sansom, D. M. CTLA-4: a moving target in immunotherapy. Blood 131, 58\u201367 (2018).","journal-title":"Blood"},{"key":"2280_CR287","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s13577-023-00893-8","volume":"36","author":"P Azimnasab-sorkhabi","year":"2023","unstructured":"Azimnasab-sorkhabi, P., Soltani-asl, M. & Kfoury Junior, J. R. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum. Cell 36, 1225\u20131232 (2023).","journal-title":"Hum. Cell"},{"key":"2280_CR288","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ymthe.2023.11.028","volume":"32","author":"PT Kennedy","year":"2024","unstructured":"Kennedy, P. T. et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol. Ther. 32, 457\u2013468 (2024).","journal-title":"Mol. Ther."},{"key":"2280_CR289","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF02788753","volume":"18","author":"P Scheipers","year":"1998","unstructured":"Scheipers, P. & Reiser, H. Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor. Immunol. Res. 18, 103\u2013115 (1998).","journal-title":"Immunol. Res."},{"key":"2280_CR290","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20874-x","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat. Commun. 12, 525 (2021).","journal-title":"Nat. Commun."},{"key":"2280_CR291","doi-asserted-by":"crossref","unstructured":"Brunner-Weinzierl, M. C. & Rudd, C. E. CTLA-4 and PD-1 control of T-Cell motility and migration: implications for tumor immunotherapy. Front. Immunol. 9, 2737 (2018).","DOI":"10.3389\/fimmu.2018.02737"},{"key":"2280_CR292","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.4049\/jimmunol.160.8.3855","volume":"160","author":"TL Walunas","year":"1998","unstructured":"Walunas, T. L. & Bluestone, J. A. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 160, 3855\u20133860 (1998).","journal-title":"J. Immunol."},{"key":"2280_CR293","doi-asserted-by":"crossref","unstructured":"Hossen, M. M. et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front. Immunol. 14, 1198365 (2023).","DOI":"10.3389\/fimmu.2023.1198365"},{"key":"2280_CR294","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40844-3","volume":"14","author":"NP Rudqvist","year":"2023","unstructured":"Rudqvist, N. P. et al. Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors. Nat. Commun. 14, 5146 (2023).","journal-title":"Nat. Commun."},{"key":"2280_CR295","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06391-x","volume":"15","author":"M Babamohamadi","year":"2024","unstructured":"Babamohamadi, M. et al. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 15, 17 (2024).","journal-title":"Cell Death Dis."},{"key":"2280_CR296","doi-asserted-by":"crossref","unstructured":"Sobhani, N. et al. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers 13, 1440 (2021).","DOI":"10.3390\/cancers13061440"},{"key":"2280_CR297","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 184 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR298","doi-asserted-by":"crossref","unstructured":"Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98\u2013106 (2016).","DOI":"10.1097\/COC.0000000000000239"},{"key":"2280_CR299","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz, M. Z. et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 40, 949\u2013982 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2280_CR300","doi-asserted-by":"crossref","unstructured":"Frey, C. & Etminan, M. Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. Antibodies 13, 59 (2024).","DOI":"10.3390\/antib13030059"},{"key":"2280_CR301","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-021-01872-3","volume":"40","author":"A Relecom","year":"2021","unstructured":"Relecom, A. et al. Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. J. Exp. Clin. Cancer Res. 40, 74 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR302","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.12.010","volume":"13","author":"L Barrueto","year":"2020","unstructured":"Barrueto, L. et al. Resistance to checkpoint inhibition in cancer immunotherapy. Transl. Oncol. 13, 100738 (2020).","journal-title":"Transl. Oncol."},{"key":"2280_CR303","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang, R. Y. et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6, e1249561 (2017).","journal-title":"Oncoimmunology"},{"key":"2280_CR304","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2326-6066.CIR-18-0291","volume":"6","author":"PA Beavis","year":"2018","unstructured":"Beavis, P. A. et al. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells. Cancer Immunol. Res. 6, 1069\u20131081 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR305","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane, J. & Gomis, R. R. TGF-\u03b2 family signaling in tumor suppression and cancer progression. Cold Spring Harb. Perspect. Biol. 9, a022277 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2280_CR306","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","volume":"22","author":"DVF Tauriello","year":"2022","unstructured":"Tauriello, D. V. F., Sancho, E. & Batlle, E. Overcoming TGF\u03b2-mediated immune evasion in cancer. Nat. Rev. Cancer 22, 25\u201344 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2280_CR307","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.04.001","volume":"71-72","author":"M Turati","year":"2023","unstructured":"Turati, M. et al. TGF-\u03b2 mediated drug resistance in solid cancer. Cytokine Growth Factor Rev. 71-72, 54\u201365 (2023).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2280_CR308","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-05-0414","volume":"11","author":"WM Grady","year":"2005","unstructured":"Grady, W. M. Transforming growth factor-\u03b2, smads, and cancer. Clin. Cancer Res 11, 3151\u20133154 (2005).","journal-title":"Clin. Cancer Res"},{"key":"2280_CR309","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00242-8","volume":"5","author":"Y Ni","year":"2021","unstructured":"Ni, Y. et al. High TGF-\u03b2 signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. NPJ Precis. Oncol. 5, 101 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"2280_CR310","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2280_CR311","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12865-021-00434-8","volume":"22","author":"YS Lee","year":"2021","unstructured":"Lee, Y. S. et al. Downregulation of NKG2DLs by TGF-\u03b2 in human lung cancer cells. BMC Immunol. 22, 44 (2021).","journal-title":"BMC Immunol."},{"key":"2280_CR312","doi-asserted-by":"crossref","unstructured":"Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, a022236 (2017).","DOI":"10.1101\/cshperspect.a022236"},{"key":"2280_CR313","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ni.1607","volume":"9","author":"Y Liu","year":"2008","unstructured":"Liu, Y. et al. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat. Immunol. 9, 632\u2013640 (2008).","journal-title":"Nat. Immunol."},{"key":"2280_CR314","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","volume":"13","author":"SH Wrzesinski","year":"2007","unstructured":"Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-\u03b2 and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262\u20135270 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR315","doi-asserted-by":"crossref","unstructured":"Hao, Y., Baker, D. & Ten Dijke, P. TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis. Int. J. Mol. Sci. 20, 2767 (2019).","DOI":"10.3390\/ijms20112767"},{"key":"2280_CR316","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu, J., Lamouille, S. & Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19, 156\u2013172 (2009).","journal-title":"Cell Res."},{"key":"2280_CR317","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00378-w","volume":"10","author":"SB Gottumukkala","year":"2024","unstructured":"Gottumukkala, S. B., Ganesan, T. S. & Palanisamy, A. Comprehensive molecular interaction map of TGF\u03b2 induced epithelial to mesenchymal transition in breast cancer. NPJ Syst. Biol. Appl. 10, 53 (2024).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"2280_CR318","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200005RR","volume":"36","author":"Z Sun","year":"2022","unstructured":"Sun, Z. et al. RNA demethylase ALKBH5 inhibits TGF-\u03b2-induced EMT by regulating TGF-\u03b2\/SMAD signaling in non-small cell lung cancer. FASEB J. 36, e22283 (2022).","journal-title":"FASEB J."},{"key":"2280_CR319","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/CCO.0000000000000006","volume":"25","author":"KL Dennis","year":"2013","unstructured":"Dennis, K. L., Blatner, N. R., Gounari, F. & Khazaie, K. Current status of interleukin-10 and regulatory T-cells in cancer. Curr. Opin. Oncol. 25, 637\u2013645 (2013).","journal-title":"Curr. Opin. Oncol."},{"key":"2280_CR320","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00262-023-03616-y","volume":"73","author":"Y Huang","year":"2024","unstructured":"Huang, Y., Zou, K., Jiang, H. & Li, Z. The complex role of IL-10 in malignant ascites: a review. Cancer Immunol. Immunother. 73, 32 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2280_CR321","doi-asserted-by":"crossref","unstructured":"Carlini, V. et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol. 14, 1161067 (2023).","DOI":"10.3389\/fimmu.2023.1161067"},{"key":"2280_CR322","first-page":"191","volume":"380","author":"MR Walter","year":"2014","unstructured":"Walter, M. R. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr. Top. Microbiol. Immunol. 380, 191\u2013212 (2014).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2280_CR323","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","volume":"217","author":"M Saraiva","year":"2019","unstructured":"Saraiva, M., Vieira, P. & O\u2019Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 217, e20190418 (2019).","journal-title":"J. Exp. Med."},{"key":"2280_CR324","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu, Y., Dong, Z. & Liu, K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J. Exp. Clin. Cancer Res. 43, 23 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR325","doi-asserted-by":"crossref","unstructured":"Zerdes, I. et al. STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer. Cancers 11, 1479 (2019).","DOI":"10.3390\/cancers11101479"},{"key":"2280_CR326","doi-asserted-by":"crossref","unstructured":"Tolomeo, M. & Cascio, A. The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int. J. Mol. Sci. 22, 603 (2021).","DOI":"10.3390\/ijms22020603"},{"key":"2280_CR327","doi-asserted-by":"publisher","first-page":"205031212110690","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar, B. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy. SAGE Open Med. 10, 20503121211069012 (2022).","journal-title":"SAGE Open Med."},{"key":"2280_CR328","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.21873\/anticanres.15110","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis, K. S. et al. Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10. Anticancer Res. 41, 3247 (2021).","journal-title":"Anticancer Res."},{"key":"2280_CR329","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.4049\/jimmunol.160.7.3188","volume":"160","author":"H Groux","year":"1998","unstructured":"Groux, H., Bigler, M., de Vries, J. E. & Roncarolo, M.-G. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 160, 3188\u20133193 (1998).","journal-title":"J. Immunol."},{"key":"2280_CR330","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li, C. et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer 19, 116 (2020).","journal-title":"Mol. Cancer"},{"key":"2280_CR331","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-022-02272-x","volume":"41","author":"N Kumari","year":"2022","unstructured":"Kumari, N. & Choi, S. H. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J. Exp. Clin. Cancer Res. 41, 68 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR332","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-023-01473-x","volume":"16","author":"X Cheng","year":"2023","unstructured":"Cheng, X. et al. Tumor-associated myeloid cells in cancer immunotherapy. J. Hematol. Oncol. 16, 71 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR333","doi-asserted-by":"publisher","first-page":"e003416","DOI":"10.1136\/jitc-2021-003416","volume":"10","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J. Immunother. Cancer 10, e003416 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2280_CR334","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J. Biomed. Sci. 26, 78 (2019).","journal-title":"J. Biomed. Sci."},{"key":"2280_CR335","doi-asserted-by":"crossref","unstructured":"Khan, A. et al. NF-\u03baB role on tumor proliferation, migration, invasion and immune escape. Cancer Gene Ther. 31, 1\u201312 (2024).","DOI":"10.1038\/s41417-024-00811-6"},{"key":"2280_CR336","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00018-023-05098-8","volume":"81","author":"N Ebrahimi","year":"2024","unstructured":"Ebrahimi, N. et al. Targeting the NF-\u03baB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cell Mol. Life Sci. 81, 106 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"2280_CR337","doi-asserted-by":"publisher","first-page":"764164","DOI":"10.3389\/fcell.2021.764164","volume":"9","author":"G Ghosh","year":"2021","unstructured":"Ghosh, G. & Wang, V. Y. Origin of the functional distinctiveness of NF-\u03baB\/p52. Front. Cell Dev. Biol. 9, 764164 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2280_CR338","doi-asserted-by":"publisher","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus, A. & Ghosh, S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1, a000034 (2009).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2280_CR339","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01433-5","volume":"22","author":"M Pakjoo","year":"2024","unstructured":"Pakjoo, M. et al. Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Commun. Signal. 22, 105 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2280_CR340","doi-asserted-by":"crossref","unstructured":"Zhang, T. et al. NF-\u03baB signaling in inflammation and cancer. MedComm 2, 618\u2013653 (2021).","DOI":"10.1002\/mco2.104"},{"key":"2280_CR341","doi-asserted-by":"crossref","unstructured":"Lalle, G., Twardowski, J. & Grinberg-Bleyer, Y. NF-\u03baB in cancer immunity: friend or foe? Cells 10, 355 (2021).","DOI":"10.3390\/cells10020355"},{"key":"2280_CR342","doi-asserted-by":"crossref","unstructured":"Betzler, A. C. et al. NF-\u03baB and its role in checkpoint control. Int. J. Mol. Sci. 21, 3949 (2020).","DOI":"10.3390\/ijms21113949"},{"key":"2280_CR343","first-page":"1","volume":"54","author":"T Matsunaga","year":"2011","unstructured":"Matsunaga, T., Saito, H. & Ikeguchi, M. Increased B7-H1 and B7-H4 expressions on circulating monocytes and tumor-associated macrophages are involved in immune evasion in patients with gastric cancer. Yonago Acta Med. 54, 1\u201310 (2011).","journal-title":"Yonago Acta Med."},{"key":"2280_CR344","doi-asserted-by":"crossref","unstructured":"Wu, X., Sun, L. & Xu, F. NF-\u03baB in cell deaths, therapeutic resistance and nanotherapy of tumors: recent advances. Pharmaceuticals 16, 783 (2023).","DOI":"10.3390\/ph16060783"},{"key":"2280_CR345","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia, Y., Shen, S. & Verma, I. M. NF-\u03baB, an active player in human cancers. Cancer Immunol. Res. 2, 823\u2013830 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2280_CR346","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40164-024-00529-z","volume":"13","author":"Q Ma","year":"2024","unstructured":"Ma, Q. et al. Versatile function of NF-\u0138B in inflammation and cancer. Exp. Hematol. Oncol. 13, 68 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2280_CR347","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.molcel.2014.03.040","volume":"54","author":"X Cai","year":"2014","unstructured":"Cai, X., Chiu, Y.-H. & Chen, Z. J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol. Cell 54, 289\u2013296 (2014).","journal-title":"Mol. Cell"},{"key":"2280_CR348","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon, J. & Bakhoum, S. F. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 10, 26\u201339 (2020).","journal-title":"Cancer Discov."},{"key":"2280_CR349","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s12276-020-0416-y","volume":"52","author":"A Basit","year":"2020","unstructured":"Basit, A. et al. The cGAS\/STING\/TBK1\/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. Exp. Mol. Med. 52, 643\u2013657 (2020).","journal-title":"Exp. Mol. Med."},{"key":"2280_CR350","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1189\/jlb.71.4.669","volume":"71","author":"E Padovan","year":"2002","unstructured":"Padovan, E., Spagnoli, G. C., Ferrantini, M. & Heberer, M. IFN-\u03b12a induces IP-10\/CXCL10 and MIG\/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J. Leukoc. Biol. 71, 669\u2013676 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"2280_CR351","doi-asserted-by":"crossref","unstructured":"Gan, Y. et al. The cGAS\/STING\u2002pathway: a novel target for cancer therapy. Front. Immunol. 12, 795401 (2022).","DOI":"10.3389\/fimmu.2021.795401"},{"key":"2280_CR352","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06418-3","volume":"15","author":"M Tang","year":"2024","unstructured":"Tang, M. et al. The P286R mutation of DNA polymerase \u03b5 activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. Cell Death Dis. 15, 69 (2024).","journal-title":"Cell Death Dis."},{"key":"2280_CR353","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110617","volume":"122","author":"Z-r Ma","year":"2023","unstructured":"Ma, Z. -r et al. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy. Int. Immunopharmacol. 122, 110617 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2280_CR354","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726 (2020).","journal-title":"Nat. Commun."},{"key":"2280_CR355","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra, V. et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clin. Cancer Res. 28, 4536\u20134550 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR356","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/ncb3615","volume":"19","author":"M-Z Wu","year":"2017","unstructured":"Wu, M.-Z. et al. miR-25\/93 mediates hypoxia-induced immunosuppression by repressing cGAS. Nat. Cell Biol. 19, 1286\u20131296 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2280_CR357","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167457","volume":"1870","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 167457 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2280_CR358","doi-asserted-by":"crossref","unstructured":"Ma, F. et al. LncRNA NEAT1 interacted with DNMT1 to regulate malignant phenotype of cancer cell and cytotoxic T cell infiltration via epigenetic inhibition of p53, cGAS, and STING in lung cancer. Front. Genet. 11, 250 (2020).","DOI":"10.3389\/fgene.2020.00250"},{"key":"2280_CR359","doi-asserted-by":"crossref","unstructured":"Storozynsky, Q. & Hitt, M. M. The impact of radiation-induced DNA damage on cGAS-STING-mediated immune responses to cancer. Int. J. Mol. Sci. 21, 8877 (2020).","DOI":"10.3390\/ijms21228877"},{"key":"2280_CR360","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214278119","volume":"119","author":"Y-t Wu","year":"2022","unstructured":"Wu, Y. -t et al. Tumor-targeted delivery of a STING agonist improves cancer immunotherapy. Proc. Natl. Acad. Sci. USA 119, e2214278119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2280_CR361","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1002\/mog2.49","volume":"2","author":"X Fan","year":"2023","unstructured":"Fan, X. et al. cGAS-STING signaling in cancer: regulation and therapeutic targeting. MedComm Oncol. 2, e49 (2023).","journal-title":"MedComm Oncol."},{"key":"2280_CR362","doi-asserted-by":"crossref","unstructured":"Borgeaud, M. et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat. Rev 120, 102614 (2023).","DOI":"10.1016\/j.ctrv.2023.102614"},{"key":"2280_CR363","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03183-3","volume":"24","author":"M Noori","year":"2024","unstructured":"Noori, M. et al. Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review. Cancer Cell Int. 24, 10 (2024).","journal-title":"Cancer Cell Int."},{"key":"2280_CR364","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"2280_CR365","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2174\/1566524022666220610094716","volume":"23","author":"S Ghahremani Dehbokri","year":"2023","unstructured":"Ghahremani Dehbokri, S. et al. CTLA-4: as an immunosuppressive immune checkpoint in breast cancer. Curr. Mol. Med. 23, 521\u2013526 (2023).","journal-title":"Curr. Mol. Med."},{"key":"2280_CR366","first-page":"3140","volume":"13","author":"C Tian","year":"2023","unstructured":"Tian, C., Wang, X. & Zhang, S. CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events. Am. J. Cancer Res. 13, 3140 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"2280_CR367","doi-asserted-by":"publisher","first-page":"154338","DOI":"10.1016\/j.prp.2023.154338","volume":"244","author":"M AmeliMojarad","year":"2023","unstructured":"AmeliMojarad, M., AmeliMojarad, M. & Cui, X. Prospective role of PD-1\/PD-L1 immune checkpoint inhibitors in GI cancer. Pathol. Res. Pract. 244, 154338 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"2280_CR368","doi-asserted-by":"publisher","first-page":"v715","DOI":"10.1093\/annonc\/mdz264.012","volume":"30","author":"E Calvo","year":"2019","unstructured":"Calvo, E. et al. 1748P - Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer. Ann. Oncol. 30, v715\u2013v716 (2019).","journal-title":"Ann. Oncol."},{"key":"2280_CR369","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/cts.12855","volume":"14","author":"J Powderly","year":"2021","unstructured":"Powderly, J. et al. Model informed dosing regimen and phase I results of the anti-PD-1 antibody budigalimab (ABBV-181). Clin. Transl. Sci. 14, 277\u2013287 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"2280_CR370","unstructured":"Desai, J. et al. Updated safety, efficacy, and pharmacokinetics (PK) results from the phase I study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. J. Immunother. Cancer. 4 (2016)."},{"key":"2280_CR371","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/1538-7445.AM2016-2226","volume":"76","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. Abstract 2226: Anti-human PD-1 antibody BGB-A317 exhibits potent immune cell activation. Cancer Res. 76, 2226\u20132226 (2016).","journal-title":"Cancer Res."},{"key":"2280_CR372","doi-asserted-by":"publisher","first-page":"viii467","DOI":"10.1093\/annonc\/mdy293.001","volume":"29","author":"JC Yao","year":"2018","unstructured":"Yao, J. C. et al. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann. Oncol. 29, viii467\u2013viii468 (2018).","journal-title":"Ann. Oncol."},{"key":"2280_CR373","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam, F., et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced\/metastatic solid tumors or lymphomas. J. Clin. Oncol. 37, 2507 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.2507"},{"key":"2280_CR374","doi-asserted-by":"crossref","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 56, 2388\u20132407 (2023).","DOI":"10.1016\/j.immuni.2023.09.001"},{"key":"2280_CR375","doi-asserted-by":"crossref","unstructured":"Prinz, L. F. et al. An anti-CD19\/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80\/86-upregulated DLBCL. Cell Rep. Med. 5 (2024).","DOI":"10.1016\/j.xcrm.2024.101421"},{"key":"2280_CR376","doi-asserted-by":"publisher","first-page":"viii416","DOI":"10.1093\/annonc\/mdy288.040","volume":"29","author":"BA Wilky","year":"2018","unstructured":"Wilky, B. A. et al. Phase I, open-label ascending dose trial of anti\u2013CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti\u2013PD-1\/PD-L1 therapy. Ann. Oncol. 29, viii416\u2013viii417 (2018).","journal-title":"Ann. Oncol."},{"key":"2280_CR377","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.annonc.2020.11.020","volume":"32","author":"R Perets","year":"2021","unstructured":"Perets, R. et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann. Oncol. 32, 395\u2013403 (2021).","journal-title":"Ann. Oncol."},{"key":"2280_CR378","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2024.42.3_suppl.484","volume":"42","author":"L Rimassa","year":"2024","unstructured":"Rimassa, L. et al. Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): phase 2 KEYSTEP-004 study. J. Clin. Oncol. 42, 484\u2013484 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2280_CR379","doi-asserted-by":"crossref","unstructured":"Lee, J. B., Kim, H. R. & Ha, S.-J. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 22, e2 (2022).","DOI":"10.4110\/in.2022.22.e2"},{"key":"2280_CR380","doi-asserted-by":"crossref","unstructured":"Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).","DOI":"10.1186\/s12943-019-1091-2"},{"key":"2280_CR381","doi-asserted-by":"crossref","unstructured":"Khan, B., Qahwaji, R. M., Alfaifi, M. S. & Mobashir, M. Nivolumab and ipilimumab acting as tormentors of advanced tumors by unleashing immune cells and associated collateral damage. Pharmaceutics. 16, 732 (2024).","DOI":"10.3390\/pharmaceutics16060732"},{"key":"2280_CR382","doi-asserted-by":"crossref","unstructured":"Keam, S. J. Tremelimumab: first approval. Drugs 83, 93\u2013102 (2023).","DOI":"10.1007\/s40265-022-01827-8"},{"key":"2280_CR383","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219\u2013242 (2010).","journal-title":"Immunol. Rev."},{"key":"2280_CR384","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1038\/s41388-021-01972-6","volume":"40","author":"B Cen","year":"2021","unstructured":"Cen, B. et al. Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer. Oncogene 40, 5984\u20135992 (2021).","journal-title":"Oncogene"},{"key":"2280_CR385","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/08916934.2021.1913582","volume":"54","author":"Z Du","year":"2021","unstructured":"Du, Z. et al. SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1\/PD-L1 axis. Autoimmunity 54, 225\u2013233 (2021).","journal-title":"Autoimmunity"},{"key":"2280_CR386","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen, X. & Zhao, B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362, k3529 (2018).","journal-title":"BMJ"},{"key":"2280_CR387","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).","journal-title":"Mol. Cancer"},{"key":"2280_CR388","doi-asserted-by":"crossref","unstructured":"Han, S. et al. Effectiveness and safety of PD-1\/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis. Front. Pharmacol. 14, 1330877 (2023).","DOI":"10.3389\/fphar.2023.1330877"},{"key":"2280_CR389","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.7150\/jca.26961","volume":"10","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Blocking the PD-1\/PD-L1 axis in dendritic cell-stimulated cytokine-induced killer cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma. J. Cancer 10, 2578\u20132587 (2019).","journal-title":"J. Cancer"},{"key":"2280_CR390","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cr.2016.77","volume":"27","author":"Z Na","year":"2017","unstructured":"Na, Z. et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 27, 147\u2013150 (2017).","journal-title":"Cell Res."},{"key":"2280_CR391","doi-asserted-by":"crossref","unstructured":"Ansell Stephen, M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s Lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","DOI":"10.1056\/NEJMoa1411087"},{"key":"2280_CR392","doi-asserted-by":"crossref","unstructured":"Parvez, A. et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front. Immunol. 14, 1296341 (2023).","DOI":"10.3389\/fimmu.2023.1296341"},{"key":"2280_CR393","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi, A. R. et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front. Oncol. 10, 91 (2020).","journal-title":"Front. Oncol."},{"key":"2280_CR394","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2018.12.015","volume":"130","author":"MA Gubens","year":"2019","unstructured":"Gubens, M. A. et al. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non\u2013small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer 130, 59\u201366 (2019).","journal-title":"Lung Cancer"},{"key":"2280_CR395","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00432-022-04286-6","volume":"149","author":"D Wankhede","year":"2023","unstructured":"Wankhede, D., Hofman, P. & Grover, S. PD-1\/PD-L1 inhibitors in treatment-na\u00efve, advanced non-small cell lung cancer patients with\u2009<\u20091% PD-L1 expression: a meta-analysis of randomized controlled trials. J. Cancer Res. Clin. Oncol. 149, 2179\u20132189 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2280_CR396","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR397","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"2280_CR398","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10588","volume":"9","author":"ME Janes","year":"2024","unstructured":"Janes, M. E. et al. Cancer vaccines in the clinic. Bioeng. Transl. Med. 9, e10588 (2024).","journal-title":"Bioeng. Transl. Med."},{"key":"2280_CR399","doi-asserted-by":"crossref","unstructured":"Cuzzubbo, S. et al. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments. Front. Immunol. 11, 615240 (2021).","DOI":"10.3389\/fimmu.2020.615240"},{"key":"2280_CR400","doi-asserted-by":"crossref","unstructured":"Kaczmarek, M. et al. Cancer vaccine therapeutics: limitations and effectiveness-a literature review. Cells 12, 2159 (2023).","DOI":"10.3390\/cells12172159"},{"key":"2280_CR401","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00262-008-0536-z","volume":"57","author":"TD De Gruijl","year":"2008","unstructured":"De Gruijl, T. D., Van Den Eertwegh, A. J. M., Pinedo, H. M. & Scheper, R. J. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57, 1569\u20131577 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"2280_CR402","doi-asserted-by":"publisher","first-page":"2300121","DOI":"10.1002\/advs.202300121","volume":"10","author":"L Diao","year":"2023","unstructured":"Diao, L. & Liu, M. Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell. Adv. Sci. 10, 2300121 (2023).","journal-title":"Adv. Sci."},{"key":"2280_CR403","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","volume":"17","author":"C Larocca","year":"2011","unstructured":"Larocca, C. & Schlom, J. Viral vector-based therapeutic cancer vaccines. J. Cancer 17, 359\u2013371 (2011).","journal-title":"J. Cancer"},{"key":"2280_CR404","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"2280_CR405","doi-asserted-by":"crossref","unstructured":"Pan, D. et al. Challenges and new directions in therapeutic cancer vaccine development. Vaccines 12, 1341 (2024).","DOI":"10.3390\/vaccines12121341"},{"key":"2280_CR406","doi-asserted-by":"crossref","unstructured":"Fleming, V. et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol. 9, 398 (2018).","DOI":"10.3389\/fimmu.2018.00398"},{"key":"2280_CR407","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","volume":"27","author":"M Taki","year":"2021","unstructured":"Taki, M. et al. Tumor immune microenvironment during epithelial\u2013mesenchymal transition. Clin. Cancer Res. 27, 4669\u20134679 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR408","doi-asserted-by":"crossref","unstructured":"Precision medicine meets cancer vaccines. Nat. Med. 29, 1287 (2023).","DOI":"10.1038\/s41591-023-02432-2"},{"key":"2280_CR409","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2280_CR410","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15229-5","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang, G. et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 11, 1395 (2020).","journal-title":"Nat. Commun."},{"key":"2280_CR411","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).","journal-title":"Nat. Commun."},{"key":"2280_CR412","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/gt.2011.176","volume":"19","author":"JD Dias","year":"2012","unstructured":"Dias, J. D. et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 19, 988\u2013998 (2012).","journal-title":"Gene Ther."},{"key":"2280_CR413","doi-asserted-by":"crossref","unstructured":"Yu, J.-L., Jang, S. R. J. & Liu, K.-Y. Exploring the interactions of oncolytic viral therapy and immunotherapy of anti-CTLA-4 for malignant melanoma mice model. Cells 12, 507 (2023).","DOI":"10.3390\/cells12030507"},{"key":"2280_CR414","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.83495","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment. Theranostics 13, 4016 (2023).","journal-title":"Theranostics"},{"key":"2280_CR415","volume":"41","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment. MedOncol. 41, 8 (2023).","journal-title":"MedOncol."},{"key":"2280_CR416","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","volume":"9","author":"G Marelli","year":"2018","unstructured":"Marelli, G., Howells, A., Lemoine, N. R. & Wang, Y. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front. Immunol. 9, 866 (2018).","journal-title":"Front. Immunol."},{"key":"2280_CR417","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos de Matos","year":"2020","unstructured":"Lemos de Matos, A., Franco, L. S. & McFadden, G. Oncolytic viruses and the immune system: the dynamic duo. Mol. Ther. Methods Clin. Dev. 17, 349\u2013358 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2280_CR418","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wang, X. & Cheng, P. Remodeling of tumor immune microenvironment by oncolytic viruses. Front. Oncol. 10, 561372 (2021).","DOI":"10.3389\/fonc.2020.561372"},{"key":"2280_CR419","doi-asserted-by":"crossref","unstructured":"Xu, L. et al. Oncolytic vaccinia virus and cancer immunotherapy. Front. Immunol. 14, 1324744 (2024).","DOI":"10.3389\/fimmu.2023.1324744"},{"key":"2280_CR420","doi-asserted-by":"crossref","unstructured":"Wu, Y.-Y. et al. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front. Cell Infect. Microbiol. 13, 1142172 (2023).","DOI":"10.3389\/fcimb.2023.1142172"},{"key":"2280_CR421","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","volume":"73","author":"M Canel","year":"2024","unstructured":"Canel, M. et al. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. Gut 73, 131\u2013155 (2024).","journal-title":"Gut"},{"key":"2280_CR422","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang, K., Halima, A. & Chan, T. A. Antigen presentation in cancer\u2014mechanisms and clinical implications for immunotherapy. Nat. Rev. Clin. Oncol. 20, 604\u2013623 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2280_CR423","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49286-x","volume":"15","author":"MJ Webb","year":"2024","unstructured":"Webb, M. J. et al. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Nat. Commun. 15, 5442 (2024).","journal-title":"Nat. Commun."},{"key":"2280_CR424","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.gt.3303098","volume":"15","author":"J Qiao","year":"2008","unstructured":"Qiao, J. et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther. 15, 604\u2013616 (2008).","journal-title":"Gene Ther."},{"key":"2280_CR425","volume":"5","author":"JD Bernstock","year":"2023","unstructured":"Bernstock, J. D. et al. Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma. Neurooncol. Adv. 5, vdad081 (2023).","journal-title":"Neurooncol. Adv."},{"key":"2280_CR426","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2280_CR427","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","volume":"6","author":"K Perica","year":"2015","unstructured":"Perica, K., Varela, J. C., Oelke, M. & Schneck, J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med. J. 6, e0004 (2015).","journal-title":"Rambam Maimonides Med. J."},{"key":"2280_CR428","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"K Kirtane","year":"2021","unstructured":"Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J. Immunother. Cancer 9, e002723 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2280_CR429","doi-asserted-by":"publisher","first-page":"eadg2697","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han, S. et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci. Adv. 9, eadg2697 (2023).","journal-title":"Sci. Adv."},{"key":"2280_CR430","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40727-7","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Nat. Commun. 14, 5123 (2023).","journal-title":"Nat. Commun."},{"key":"2280_CR431","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101465","volume":"5","author":"M St Paul","year":"2024","unstructured":"St Paul, M. et al. Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy. Cell Rep. Med. 5, 101465 (2024).","journal-title":"Cell Rep. Med."},{"key":"2280_CR432","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1200\/JCO.22.01618","volume":"41","author":"DJ Olson","year":"2023","unstructured":"Olson, D. J. & Odunsi, K. Adoptive cell therapy for nonhematologic solid tumors. J. Clin. Oncol. 41, 3397\u20133407 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2280_CR433","doi-asserted-by":"crossref","unstructured":"Nasution, A. A. et al. Immune evasion through loss of MHC class I antigen presentation. Biomol. Health Sci. J. 6, 25\u201330 (2023).","DOI":"10.4103\/bhsj.bhsj_35_22"},{"key":"2280_CR434","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-024-02979-z","volume":"43","author":"Q Yang","year":"2024","unstructured":"Yang, Q. et al. LATS1\/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression. J. Exp. Clin. Cancer Res. 43, 54 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR435","doi-asserted-by":"crossref","unstructured":"Du, S. et al. Adoptive cell therapy for cancer treatment. Exploration 3, 20210058 (2023).","DOI":"10.1002\/EXP.20210058"},{"key":"2280_CR436","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan, M. W., Wilgenhof, S. & Haanen, J. Adoptive cellular therapies: the current landscape. Virchows Arch. 474, 449\u2013461 (2019).","journal-title":"Virchows Arch."},{"key":"2280_CR437","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068956","volume":"378","author":"JE Maakaron","year":"2022","unstructured":"Maakaron, J. E., Hu, M. & El Jurdi, N. Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. BMJ 378, e068956 (2022).","journal-title":"BMJ"},{"key":"2280_CR438","doi-asserted-by":"crossref","unstructured":"Chen, R. et al. CAR-T treatment for cancer: prospects and challenges. Front. Oncol. 13, 1288383 (2023).","DOI":"10.3389\/fonc.2023.1288383"},{"key":"2280_CR439","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1615\/CritRevImmunol.2019030788","volume":"39","author":"P Sharma","year":"2019","unstructured":"Sharma, P. & Kranz, D. M. T cell receptors for gene transfer in adoptive T cell therapy. Crit. Rev. Immunol. 39, 105\u2013122 (2019).","journal-title":"Crit. Rev. Immunol."},{"key":"2280_CR440","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1182\/blood-2023-189346","volume":"142","author":"S Simon","year":"2023","unstructured":"Simon, S. et al. Multispecific hybrid T cell receptors for sensitive targeting of cancer. Blood 142, 4822\u20134822 (2023).","journal-title":"Blood"},{"key":"2280_CR441","doi-asserted-by":"crossref","unstructured":"Uscanga-Palomeque, A. C. et al. CAR-T cell therapy: from the shop to cancer therapy. Int. J. Mol. Sci. 24, 15688 (2023).","DOI":"10.3390\/ijms242115688"},{"key":"2280_CR442","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu, J., Luo, W., Li, C. & Mei, H. Targeting CD22 for B-cell hematologic malignancies. Exp. Hematol. Oncol. 12, 90 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"2280_CR443","first-page":"802","volume":"14","author":"ML Davila","year":"2016","unstructured":"Davila, M. L. & Brentjens, R. J. CD19-targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin. Adv. Hematol. Oncol. 14, 802\u2013808 (2016).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"2280_CR444","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro, A. et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol. Blood Marrow Transpl. 26, 26\u201333 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2280_CR445","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2280_CR446","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra, A., Maiti, R., Mohan, P. & Gupta, P. Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions. Eur. J. Haematol. 112, 211\u2013222 (2024).","journal-title":"Eur. J. Haematol."},{"key":"2280_CR447","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"2280_CR448","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J. Clin. Med. 12, 6124 (2023).","DOI":"10.3390\/jcm12196124"},{"key":"2280_CR449","doi-asserted-by":"crossref","unstructured":"Genoud, V. & Migliorini, D. An overview of cytokine release syndrome and other side effects of CAR-T cell therapy. Praxis 112, 189\u2013193 (2023).","DOI":"10.1024\/1661-8157\/a003980"},{"key":"2280_CR450","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua, L. A. et al. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol. Ther. Oncolytics 25, 69\u201377 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2280_CR451","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi, A. et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front. Immunol. 14, 1113882 (2023).","journal-title":"Front. Immunol."},{"key":"2280_CR452","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen, T., Wang, M., Chen, Y. & Liu, Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 24, 133 (2024).","journal-title":"Cancer Cell Int."},{"key":"2280_CR453","doi-asserted-by":"crossref","unstructured":"Gonzalez, V. D. et al. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. Cell Rep. 36, 9 (2021).","DOI":"10.1016\/j.celrep.2021.109632"},{"key":"2280_CR454","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s11095-005-8177-9","volume":"22","author":"S Hermeling","year":"2005","unstructured":"Hermeling, S. et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22, 1997\u20132006 (2005).","journal-title":"Pharm. Res."},{"key":"2280_CR455","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","volume":"28","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Lifileucel: first approval. Mol. Diagn. Ther. 28, 339\u2013344 (2024).","journal-title":"Mol. Diagn. Ther."},{"key":"2280_CR456","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"A-M Tsimberidou","year":"2021","unstructured":"Tsimberidou, A.-M. et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J. Hematol. Oncol. 14, 102 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR457","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","volume":"28","author":"R Yarza","year":"2023","unstructured":"Yarza, R. et al. Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis. Oncologist 28, e406\u2013e415 (2023).","journal-title":"Oncologist"},{"key":"2280_CR458","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu, D. et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat. Commun. 14, 6389 (2023).","journal-title":"Nat. Commun."},{"key":"2280_CR459","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","volume":"22","author":"CA Klebanoff","year":"2023","unstructured":"Klebanoff, C. A. et al. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug Discov. 22, 996\u20131017 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2280_CR460","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol. Cancer 19, 79 (2020).","journal-title":"Mol. Cancer"},{"key":"2280_CR461","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1002\/mog2.59","volume":"3","author":"L Tao","year":"2024","unstructured":"Tao, L. et al. Epigenetic regulation in cancer therapy: from mechanisms to clinical advances. MedComm Oncol. 3, e59 (2024).","journal-title":"MedComm Oncol."},{"key":"2280_CR462","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05878-x","volume":"14","author":"S Long","year":"2023","unstructured":"Long, S. et al. Epigenetically modified AP-2\u03b1 by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression. Cell Death Dis. 14, 365 (2023).","journal-title":"Cell Death Dis."},{"key":"2280_CR463","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3748\/wjg.v28.i18.1934","volume":"28","author":"W Sim","year":"2022","unstructured":"Sim, W. et al. Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. World J. Gastroenterol. 28, 1934\u20131945 (2022).","journal-title":"World J. Gastroenterol."},{"key":"2280_CR464","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825\u20131863 (2024).","journal-title":"Cancer Cell"},{"key":"2280_CR465","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s12276-021-00612-z","volume":"53","author":"A Berglund","year":"2021","unstructured":"Berglund, A., Putney, R. M., Hamaidi, I. & Kim, S. Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. Exp. Mol. Med. 53, 761\u2013771 (2021).","journal-title":"Exp. Mol. Med."},{"key":"2280_CR466","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01956-6","volume":"23","author":"L Cheng","year":"2024","unstructured":"Cheng, L. et al. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison. Mol. Cancer 23, 77 (2024).","journal-title":"Mol. Cancer"},{"key":"2280_CR467","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell, J. et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin. Pharmacol. Ther. 106, 781\u2013791 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2280_CR468","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi, L., Vardhana, S. A. & Salles, G. A. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood 141, 467\u2013480 (2023).","journal-title":"Blood"},{"key":"2280_CR469","doi-asserted-by":"crossref","unstructured":"Hoffman, L. & Gore, L. Blinatumomab, a Bi-Specific Anti-CD19\/CD3 BiTE\u00ae antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front. Oncol. 4, 63 (2014).","DOI":"10.3389\/fonc.2014.00063"},{"key":"2280_CR470","doi-asserted-by":"crossref","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013487 (2017).","DOI":"10.1056\/NEJMoa1609783"},{"key":"2280_CR471","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113303","volume":"14","author":"X Xiao","year":"2023","unstructured":"Xiao, X. et al. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Front. Immunol. 14, 1113303 (2023).","journal-title":"Front. Immunol."},{"key":"2280_CR472","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2256904","volume":"19","author":"T Huan","year":"2023","unstructured":"Huan, T. et al. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer. Hum. Vaccin. Immunother. 19, 2256904 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2280_CR473","doi-asserted-by":"crossref","unstructured":"Nikkhoi, S. K. et al. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Front. Immunol. 13, 1039969 (2023).","DOI":"10.3389\/fimmu.2022.1039969"},{"key":"2280_CR474","doi-asserted-by":"publisher","first-page":"e008295","DOI":"10.1136\/jitc-2023-008295","volume":"12","author":"S Khoshtinat Nikkhoi","year":"2024","unstructured":"Khoshtinat Nikkhoi, S. et al. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice. J. Immunother. Cancer 12, e008295 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2280_CR475","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares, L. et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in Second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J. Thorac. Oncol. 15, 1210\u20131222 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"2280_CR476","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01562-5","volume":"22","author":"T Li","year":"2024","unstructured":"Li, T. et al. The enhanced antitumor activity of bispecific antibody targeting PD-1\/PD-L1 signaling. Cell Commun. Signal 22, 179 (2024).","journal-title":"Cell Commun. Signal"},{"key":"2280_CR477","doi-asserted-by":"publisher","first-page":"864301","DOI":"10.3389\/fonc.2022.864301","volume":"12","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. Nano drug delivery system for tumor immunotherapy: next-generation therapeutics. Front. Oncol. 12, 864301 (2022).","journal-title":"Front. Oncol."},{"key":"2280_CR478","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1230893","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors. Front. Immunol. 14, 1230893 (2023).","journal-title":"Front. Immunol."},{"key":"2280_CR479","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi, M. et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol. Cancer 22, 169 (2023).","journal-title":"Mol. Cancer"},{"key":"2280_CR480","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.phrs.2017.05.004","volume":"126","author":"S Yang","year":"2017","unstructured":"Yang, S. & Gao, H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharm. Res. 126, 97\u2013108 (2017).","journal-title":"Pharm. Res."},{"key":"2280_CR481","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.7150\/thno.37568","volume":"9","author":"M Saeed","year":"2019","unstructured":"Saeed, M. et al. Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics 9, 7981 (2019).","journal-title":"Theranostics"},{"key":"2280_CR482","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02311-z","volume":"22","author":"Z Sun","year":"2024","unstructured":"Sun, Z. et al. The quest for nanoparticle-powered vaccines in cancer immunotherapy. J. Nanobiotechnol. 22, 61 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2280_CR483","doi-asserted-by":"crossref","unstructured":"Schunke, J., Mail\u00e4nder, V., Landfester, K. & Fichter, M. Delivery of immunostimulatory cargos in nanocarriers enhances anti-tumoral nanovaccine efficacy. Int. J. Mol. Sci. 24, 12174 (2023).","DOI":"10.3390\/ijms241512174"},{"key":"2280_CR484","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-022-01320-5","volume":"15","author":"H Tian","year":"2022","unstructured":"Tian, H. et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J. Hematol. Oncol. 15, 132 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR485","doi-asserted-by":"crossref","unstructured":"Yao, Y. et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci. 7, 193 (2020).","DOI":"10.3389\/fmolb.2020.00193"},{"key":"2280_CR486","doi-asserted-by":"publisher","first-page":"2119020","DOI":"10.1080\/21645515.2022.2119020","volume":"18","author":"Q Yin","year":"2022","unstructured":"Yin, Q., Wang, Y., Xiang, Y. & Xu, F. Nanovaccines: merits, and diverse roles in boosting antitumor immune responses. Hum. Vaccin Immunother. 18, 2119020 (2022).","journal-title":"Hum. Vaccin Immunother."},{"key":"2280_CR487","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1211262","volume":"13","author":"M Yao","year":"2023","unstructured":"Yao, M. et al. Research progress of nanovaccine in anti-tumor immunotherapy. Front. Oncol. 13, 1211262 (2023).","journal-title":"Front. Oncol."},{"key":"2280_CR488","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01476-9","volume":"20","author":"GSR Raju","year":"2022","unstructured":"Raju, G. S. R. et al. Nanoparticles mediated tumor microenvironment modulation: current advances and applications. J. Nanobiotechnol. 20, 274 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"2280_CR489","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41401-020-0424-4","volume":"41","author":"B Sun","year":"2020","unstructured":"Sun, B., Hyun, H., Li, L. -t & Wang, A. Z. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta Pharm. Sin. 41, 970\u2013985 (2020).","journal-title":"Acta Pharm. Sin."},{"key":"2280_CR490","doi-asserted-by":"crossref","unstructured":"Wu, P. et al. Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications. Pharmaceutics. 14, 1990 (2022).","DOI":"10.3390\/pharmaceutics14101990"},{"key":"2280_CR491","doi-asserted-by":"publisher","first-page":"2202063","DOI":"10.1002\/adhm.202202063","volume":"12","author":"R Cheng","year":"2023","unstructured":"Cheng, R. & Santos, H. A. Smart nanoparticle-based platforms for regulating tumor microenvironment and cancer immunotherapy. Adv. Health. Mater. 12, 2202063 (2023).","journal-title":"Adv. Health. Mater."},{"key":"2280_CR492","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","volume":"17","author":"Q Lu","year":"2024","unstructured":"Lu, Q. et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J. Hematol. Oncol. 17, 16 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR493","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen, C., Wang, Z., Ding, Y. & Qin, Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front. Immunol. 14, 1133308 (2023).","journal-title":"Front. Immunol."},{"key":"2280_CR494","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","volume":"29","author":"A Tiwari","year":"2022","unstructured":"Tiwari, A., Trivedi, R. & Lin, S.-Y. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J. Biomed. Sci. 29, 83 (2022).","journal-title":"J. Biomed. Sci."},{"key":"2280_CR495","doi-asserted-by":"crossref","unstructured":"Park, K., Veena, M. S. & Shin, D. S. Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies. Front. Cell Dev. Biol. 10, 830208 (2022).","DOI":"10.3389\/fcell.2022.830208"},{"key":"2280_CR496","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta, M. T., Antignani, A. & Fitzgerald, D. J. Managing the TME to improve the efficacy of cancer therapy. Front. Immunol. 13, 954992 (2022).","journal-title":"Front. Immunol."},{"key":"2280_CR497","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"D-R Wang","year":"2022","unstructured":"Wang, D.-R., Wu, X.-L. & Sun, Y.-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Target. Ther. 7, 331 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2280_CR498","doi-asserted-by":"crossref","unstructured":"Yang, T. et al. Vascular normalization: a new window opened for cancer therapies. Front. Oncol. 11, 719836 (2021).","DOI":"10.3389\/fonc.2021.719836"},{"key":"2280_CR499","doi-asserted-by":"publisher","first-page":"1291530","DOI":"10.3389\/fimmu.2023.1291530","volume":"14","author":"C Qian","year":"2023","unstructured":"Qian, C. et al. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Front. Immunol. 14, 1291530 (2023).","journal-title":"Front. Immunol."},{"key":"2280_CR500","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101626","volume":"5","author":"F Mpekris","year":"2024","unstructured":"Mpekris, F. et al. Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy. Cell Rep. Med. 5, 101626 (2024).","journal-title":"Cell Rep. Med."},{"key":"2280_CR501","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf, K. et al. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front. Immunol. 12, 656364 (2021).","journal-title":"Front. Immunol."},{"key":"2280_CR502","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1091779","volume":"13","author":"D Zhou","year":"2022","unstructured":"Zhou, D. et al. The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment. Front. Pharmacol. 13, 1091779 (2022).","journal-title":"Front. Pharmacol."},{"key":"2280_CR503","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan, S. & Geschwind, J.-F. H. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol. Cancer 12, 152 (2013).","journal-title":"Mol. Cancer"},{"key":"2280_CR504","doi-asserted-by":"crossref","unstructured":"Chelakkot, C., Chelakkot, V. S., Shin, Y. & Song, K. Modulating glycolysis to improve cancer therapy. Int. J. Mol. Sci. 24, 2606 (2023).","DOI":"10.3390\/ijms24032606"},{"key":"2280_CR505","doi-asserted-by":"crossref","unstructured":"Chen, B. et al. The love-hate relationship between TGF-\u03b2 signaling and the immune system during development and tumorigenesis. Front. Immunol. 13, 891268 (2022).","DOI":"10.3389\/fimmu.2022.891268"},{"key":"2280_CR506","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","volume":"31","author":"L Yang","year":"2010","unstructured":"Yang, L., Pang, Y. & Moses, H. L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220\u2013227 (2010).","journal-title":"Trends Immunol."},{"key":"2280_CR507","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/bjc.2014.348","volume":"111","author":"J Naidoo","year":"2014","unstructured":"Naidoo, J., Page, D. B. & Wolchok, J. D. Immune modulation for cancer therapy. Br. J. Cancer 111, 2214\u20132219 (2014).","journal-title":"Br. J. Cancer"},{"key":"2280_CR508","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","volume":"229","author":"M Croft","year":"2009","unstructured":"Croft, M., So, T., Duan, W. & Soroosh, P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol. Rev. 229, 173\u2013191 (2009).","journal-title":"Immunol. Rev."},{"key":"2280_CR509","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11912-022-01265-5","volume":"24","author":"R Yadav","year":"2022","unstructured":"Yadav, R. & Redmond, W. L. Current clinical trial landscape of OX40 agonists. Curr. Oncol. Rep. 24, 951\u2013960 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"2280_CR510","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty, G. L., Li, Y. & Long, K. B. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev. Anticancer Ther. 17, 175\u2013186 (2017).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2280_CR511","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-020-02814-2","volume":"70","author":"EL Filbert","year":"2021","unstructured":"Filbert, E. L. et al. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol. Immunother. 70, 1853\u20131865 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2280_CR512","doi-asserted-by":"crossref","unstructured":"Salomon, R. & Dahan, R. Next generation CD40 Agonistic antibodies for cancer immunotherapy. Front. Immunol. 13, 940674 (2022).","DOI":"10.3389\/fimmu.2022.940674"},{"key":"2280_CR513","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14712598.2024.2357714","volume":"24","author":"H Andersson","year":"2024","unstructured":"Andersson, H. et al. Next-generation CD40 agonists for cancer immunotherapy. Expert Opin. Biol. Ther. 24, 351\u2013363 (2024).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2280_CR514","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-23-1014","volume":"30","author":"SH Lim","year":"2024","unstructured":"Lim, S. H., Beers, S. A., Al-Shamkhani, A. & Cragg, M. S. Agonist antibodies for cancer immunotherapy: history, hopes, and challenges. Clin. Cancer Res. 30, 1712\u20131723 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR515","doi-asserted-by":"crossref","unstructured":"Czajka-Francuz, P. et al. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front. Oncol. 13, 1200646 (2023).","DOI":"10.3389\/fonc.2023.1200646"},{"key":"2280_CR516","doi-asserted-by":"publisher","first-page":"S1581","DOI":"10.21037\/jtd.2018.02.79","volume":"10","author":"C Donini","year":"2018","unstructured":"Donini, C. et al. Next generation immune-checkpoints for cancer therapy. J. Thorac. Dis. 10, S1581\u2013s1601 (2018).","journal-title":"J. Thorac. Dis."},{"key":"2280_CR517","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J. Hematol. Oncol. 15, 111 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR518","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40364-023-00551-z","volume":"12","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy. Biomark. Res. 12, 2 (2024).","journal-title":"Biomark. Res."},{"key":"2280_CR519","doi-asserted-by":"crossref","unstructured":"Huang, M. et al. Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies. Front. Immunol. 15, 1399926 (2024).","DOI":"10.3389\/fimmu.2024.1399926"},{"key":"2280_CR520","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2280_CR521","doi-asserted-by":"crossref","unstructured":"Said, S. S. & Ibrahim, W. N. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics 15, 1143 (2023).","DOI":"10.3390\/pharmaceutics15041143"},{"key":"2280_CR522","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-3-319-67577-0_14","volume":"1036","author":"AJR McGray","year":"2017","unstructured":"McGray, A. J. R. & Bramson, J. Adaptive resistance to cancer immunotherapy. Adv. Exp. Med. Biol. 1036, 213\u2013227 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2280_CR523","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide, T. N., Wilmott, J. S., Scolyer, R. A. & Long, G. V. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin. Cancer Res. 24, 1260\u20131270 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR524","doi-asserted-by":"crossref","unstructured":"Yan, H. et al. Exercise sensitizes PD-1\/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma. Front. Immunol. 14, 1265914 (2023).","DOI":"10.3389\/fimmu.2023.1265914"},{"key":"2280_CR525","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1007\/s00432-022-04440-0","volume":"149","author":"M Davern","year":"2023","unstructured":"Davern, M. et al. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy. J. Cancer Res. Clin. Oncol. 149, 5377\u20135395 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2280_CR526","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1078-0432.CCR-21-1466","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima, E. C. et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin. Cancer Res. 28, 446\u2013451 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR527","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1158\/1078-0432.CCR-20-4338","volume":"27","author":"PJ Vellanki","year":"2021","unstructured":"Vellanki, P. J. et al. FDA approval summary: Nivolumab with ipilimumab and chemotherapy for metastatic non\u2013small cell lung cancer, a collaborative project Orbis review. Clin. Cancer Res. 27, 3522\u20133527 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR528","doi-asserted-by":"crossref","unstructured":"Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4, e126908 (2019).","DOI":"10.1172\/jci.insight.126908"},{"key":"2280_CR529","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1146\/annurev.pathmechdis.3.121806.151505","volume":"3","author":"MCU Cheang","year":"2008","unstructured":"Cheang, M. C. U., van de Rijn, M. & Nielsen, T. O. Gene expression profiling of breast cancer. Annu. Rev. Pathol. Mech. Dis. 3, 67\u201397 (2008).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"2280_CR530","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/intimm\/dxac013","volume":"34","author":"J Nagasaki","year":"2022","unstructured":"Nagasaki, J. & Togashi, Y. A variety of \u2018exhausted\u2019T cells in the tumor microenvironment. Int. Immunol. 34, 563\u2013570 (2022).","journal-title":"Int. Immunol."},{"key":"2280_CR531","doi-asserted-by":"crossref","unstructured":"Zhao, J., Shi, Y. & Cao, G. The application of single-cell RNA sequencing in the inflammatory tumor microenvironment. Biomolecules 13, 344 (2023).","DOI":"10.3390\/biom13020344"},{"key":"2280_CR532","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.3390\/cancers14246115","volume":"14","author":"A Telekes","year":"2022","unstructured":"Telekes, A. & Horv\u00e1th, A. The role of cell-free DNA in cancer treatment decision making. Cancers 14, 6115 (2022).","journal-title":"Cancers"},{"key":"2280_CR533","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/cancers12030743","volume":"12","author":"TJ Mathias","year":"2020","unstructured":"Mathias, T. J., Chang, K. T., Martin, S. S. & Vitolo, M. I. Gauging the impact of cancer treatment modalities on circulating tumor cells (CTCs). Cancers 12, 743 (2020).","journal-title":"Cancers"},{"key":"2280_CR534","doi-asserted-by":"publisher","first-page":"955","DOI":"10.20892\/j.issn.2095-3941.2021.0032","volume":"18","author":"K Kiyotani","year":"2021","unstructured":"Kiyotani, K., Toyoshima, Y. & Nakamura, Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol. Med. 18, 955 (2021).","journal-title":"Cancer Biol. Med."},{"key":"2280_CR535","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/2159-8290.CD-16-0146","volume":"6","author":"R Mandal","year":"2016","unstructured":"Mandal, R. & Chan, T. A. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 6, 703\u2013713 (2016).","journal-title":"Cancer Discov."},{"key":"2280_CR536","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0045-9","volume":"4","author":"S Delhalle","year":"2018","unstructured":"Delhalle, S. et al. A roadmap towards personalized immunology. NPJ Syst. Biol. Appl. 4, 9 (2018).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"2280_CR537","doi-asserted-by":"publisher","first-page":"437","DOI":"10.32604\/or.2023.029924","volume":"31","author":"H Guan","year":"2023","unstructured":"Guan, H. et al. Tumor neoantigens: novel strategies for application of cancer immunotherapy. Oncol. Res. 31, 437 (2023).","journal-title":"Oncol. Res."},{"key":"2280_CR538","doi-asserted-by":"crossref","unstructured":"Jiang, A. et al. Editorial: Multi-omics approaches for decoding heterogeneity in cancer immunotherapy. Front. Pharmacol. 14, 1324212 (2023).","DOI":"10.3389\/fphar.2023.1324212"},{"key":"2280_CR539","doi-asserted-by":"crossref","unstructured":"Yan, Y. et al. Cross-omics strategies and personalised options for lung cancer immunotherapy. Front. Immunol. 15, 1471409 (2024).","DOI":"10.3389\/fimmu.2024.1471409"},{"key":"2280_CR540","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.21037\/tlcr-24-594","volume":"13","author":"A Mogenet","year":"2024","unstructured":"Mogenet, A., Greillier, L. & Tomasini, P. Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?. Transl. Lung Cancer Res 13, 2856\u20132860 (2024).","journal-title":"Transl. Lung Cancer Res"},{"key":"2280_CR541","doi-asserted-by":"crossref","unstructured":"Chu, X. et al. Multi-omics approaches in immunological research. Front. Immunol. 12, 668045 (2021).","DOI":"10.3389\/fimmu.2021.668045"},{"key":"2280_CR542","doi-asserted-by":"crossref","unstructured":"Finotello, F. & Eduati, F. Multi-omics profiling of the tumor microenvironment: paving the way to precision immuno-oncology. Front. Oncol. 8, 430 (2018).","DOI":"10.3389\/fonc.2018.00430"},{"key":"2280_CR543","doi-asserted-by":"crossref","unstructured":"Dosil, S. G., Rodr\u00edguez-Gal\u00e1n, A., S\u00e1nchez-Madrid, F. & Fern\u00e1ndez-Messina, L. MicroRNAs in T cell-immunotherapy. Int. J. Mol. Sci. 24, 250 (2023).","DOI":"10.3390\/ijms24010250"},{"key":"2280_CR544","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1245\/s10434-018-07117-6","volume":"26","author":"X Zheng","year":"2019","unstructured":"Zheng, X. et al. MiR-21 participates in the PD-1\/PD-L1 pathway-mediated imbalance of Th17\/Treg cells in patients after gastric cancer resection. Ann. Surg. Oncol. 26, 884\u2013893 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"2280_CR545","doi-asserted-by":"crossref","unstructured":"Kalkusova, K., Taborska, P., Stakheev, D. & Smrz, D. The role of miR-155 in antitumor immunity. Cancers 14, 5414 (2022).","DOI":"10.3390\/cancers14215414"},{"key":"2280_CR546","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1158\/0008-5472.CAN-14-2331","volume":"75","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell\u2013dependent mechanism. Cancer Res. 75, 519\u2013531 (2015).","journal-title":"Cancer Res."},{"key":"2280_CR547","doi-asserted-by":"crossref","unstructured":"Liang, L., Xu, X., Li, J. & Yang, C. Interaction between microRNAs and myeloid-derived suppressor cells in tumor microenvironment. Front. Immunol. 13, 883683 (2022).","DOI":"10.3389\/fimmu.2022.883683"},{"key":"2280_CR548","doi-asserted-by":"publisher","first-page":"e3100","DOI":"10.1038\/cddis.2017.495","volume":"8","author":"E Slab\u00e1kov\u00e1","year":"2017","unstructured":"Slab\u00e1kov\u00e1, E., Culig, Z., Rem\u0161\u00edk, J. & Sou\u010dek, K. Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 8, e3100\u2013e3100 (2017).","journal-title":"Cell Death Dis."},{"key":"2280_CR549","doi-asserted-by":"crossref","unstructured":"Jiang, M. et al. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. J Immunother Cancer. 10, e005241 (2022).","DOI":"10.1136\/jitc-2022-005241"},{"key":"2280_CR550","doi-asserted-by":"crossref","unstructured":"Anastasiadou, E. et al. MiR-200c-3p contrasts PD-L1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of \u03b2-catenin and c-Myc. Cells 10, 519 (2021).","DOI":"10.3390\/cells10030519"},{"key":"2280_CR551","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/leu.2017.336","volume":"32","author":"C Botta","year":"2018","unstructured":"Botta, C. et al. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia 32, 1003\u20131015 (2018).","journal-title":"Leukemia"},{"key":"2280_CR552","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06791-7","volume":"15","author":"AS Pathania","year":"2024","unstructured":"Pathania, A. S. et al. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma. Cell Death Dis. 15, 428 (2024).","journal-title":"Cell Death Dis."},{"key":"2280_CR553","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-12-1383","volume":"72","author":"MZ Noman","year":"2012","unstructured":"Noman, M. Z. et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 72, 4629\u20134641 (2012).","journal-title":"Cancer Res."},{"key":"2280_CR554","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canlet.2019.02.051","volume":"451","author":"J Jeffries","year":"2019","unstructured":"Jeffries, J., Zhou, W., Hsu, A. Y. & Deng, Q. miRNA-223 at the crossroads of inflammation and cancer. Cancer Lett. 451, 136\u2013141 (2019).","journal-title":"Cancer Lett."},{"key":"2280_CR555","first-page":"1118","volume":"9","author":"M Yeh","year":"2019","unstructured":"Yeh, M. et al. Pivotal role of microRNA-138 in human cancers. Am. J. Cancer Res. 9, 1118\u20131126 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"2280_CR556","doi-asserted-by":"crossref","unstructured":"Song, N. et al. MicroRNA-138-5p suppresses non-small cell lung cancer cells by targeting PD-L1\/PD-1 to regulate tumor microenvironment. Front. Cell Dev. Biol. 8, 540 (2020).","DOI":"10.3389\/fcell.2020.00746"},{"key":"2280_CR557","doi-asserted-by":"crossref","unstructured":"Daveri, E. et al. microRNAs shape myeloid cell-mediated resistance to cancer immunotherapy. Front. Immunol. 11, 1214 (2020).","DOI":"10.3389\/fimmu.2020.01214"},{"key":"2280_CR558","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-00848-8","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi, M. et al. The role of cancer-derived microRNAs in cancer immune escape. J. Hematol. Oncol. 13, 25 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2280_CR559","doi-asserted-by":"publisher","first-page":"9560","DOI":"10.1111\/jcmm.15367","volume":"24","author":"X Yao","year":"2020","unstructured":"Yao, X. et al. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages. J. Cell Mol. Med. 24, 9560\u20139573 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"2280_CR560","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009774","volume":"12","author":"C Vaxevanis","year":"2024","unstructured":"Vaxevanis, C., Bachmann, M. & Seliger, B. Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy. J. Immunother. Cancer 12, e009774 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2280_CR561","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7150\/ijms.44377","volume":"17","author":"J Li","year":"2020","unstructured":"Li, J. et al. miR-19 regulates the expression of interferon-induced genes and MHC class I genes in human cancer cells. Int. J. Med. Sci. 17, 953\u2013964 (2020).","journal-title":"Int. J. Med. Sci."},{"key":"2280_CR562","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/cr.2014.121","volume":"24","author":"Y Yin","year":"2014","unstructured":"Yin, Y. et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 24, 1164\u20131180 (2014).","journal-title":"Cell Res."},{"key":"2280_CR563","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-022-02553-5","volume":"42","author":"F Orso","year":"2023","unstructured":"Orso, F. et al. Stroma-derived miR-214 coordinates tumor dissemination. J. Exp. Clin. Cancer Res. 42, 20 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR564","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.bbrc.2012.12.097","volume":"431","author":"F Gao","year":"2013","unstructured":"Gao, F. et al. miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 431, 610\u2013616 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2280_CR565","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1158\/0008-5472.CAN-13-2563","volume":"74","author":"B Wang","year":"2014","unstructured":"Wang, B. et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 74, 5746\u20135757 (2014).","journal-title":"Cancer Res."},{"key":"2280_CR566","doi-asserted-by":"crossref","unstructured":"Zhang, Z. et al. The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies. Front. Immunol. 12, 807895 (2022).","DOI":"10.3389\/fimmu.2021.807895"},{"key":"2280_CR567","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bbrc.2017.05.074","volume":"488","author":"L Jia","year":"2017","unstructured":"Jia, L. et al. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem. Biophys. Res. Commun. 488, 425\u2013431 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2280_CR568","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41420-024-02182-1","volume":"10","author":"R Yadav","year":"2024","unstructured":"Yadav, R. et al. The miRNA and PD-1\/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer. Cell Death Discov. 10, 414 (2024).","journal-title":"Cell Death Discov."},{"key":"2280_CR569","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.gene.2016.06.035","volume":"591","author":"DD Wang","year":"2016","unstructured":"Wang, D. D. et al. miR-197: a novel biomarker for cancers. Gene 591, 313\u2013319 (2016).","journal-title":"Gene"},{"key":"2280_CR570","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08989-2","volume":"10","author":"A-C Frank","year":"2019","unstructured":"Frank, A.-C. et al. Apoptotic tumor cell-derived microRNA-375 uses CD36 to alter the tumor-associated macrophage phenotype. Nat. Commun. 10, 1135 (2019).","journal-title":"Nat. Commun."},{"key":"2280_CR571","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14737159.2023.2233902","volume":"23","author":"M Tufail","year":"2023","unstructured":"Tufail, M. The MALAT1-breast cancer interplay: insights and implications. Expert Rev. Mol. Diagn. 23, 665\u2013678 (2023).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"2280_CR572","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. HOTAIR up-regulation activates NF-\u03baB to induce immunoescape in gliomas. Front. Immunol. 12, 785463 (2021).","DOI":"10.3389\/fimmu.2021.785463"},{"key":"2280_CR573","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Zhu, Y., Xie, Y. & Ma, X. The role of long non-coding RNAs in immunotherapy resistance. Front. Oncol. 9, 1292 (2019).","DOI":"10.3389\/fonc.2019.01292"},{"key":"2280_CR574","doi-asserted-by":"crossref","unstructured":"Yi, K. et al. PTRF\/Cavin-1 as a novel RNA-binding protein expedites the NF-\u03baB\/PD-L1 axis by stabilizing lncRNA NEAT1, contributing to tumorigenesis and immune evasion in glioblastoma. Front. Immunol. 12, 802795 (2022).","DOI":"10.3389\/fimmu.2021.802795"},{"key":"2280_CR575","doi-asserted-by":"crossref","unstructured":"Wang, X., Wang, X., Xu, M. & Sheng, W. Emerging roles of long noncoding RNAs in immuno-oncology. Front. Cell Dev. Biol. 9, 722904 (2021).","DOI":"10.3389\/fcell.2021.722904"},{"key":"2280_CR576","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41392-020-0129-7","volume":"5","author":"C Ni","year":"2020","unstructured":"Ni, C. et al. Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+\u03b3\u03b41 Treg cells. Signal Transduct. Target. Ther. 5, 41 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2280_CR577","doi-asserted-by":"crossref","unstructured":"Song, E., Su, S. & Huang, D. Abstract P4-06-27: LncRNA NKILA promotes tumour immune evasion by sensitizing tumour-specific t cells to activation-induced cell death. Cancer Res. 79, P4-06 (2019).","DOI":"10.1158\/1538-7445.SABCS18-P4-06-27"},{"key":"2280_CR578","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/1538-7445.AM2018-128","volume":"78","author":"E Song","year":"2018","unstructured":"Song, E. Abstract 128: NKILA lncRNA promotes tumor immune evasion by mediating activation-induced cell death in tumor-specific CTLs. Cancer Res. 78, 128\u2013128 (2018).","journal-title":"Cancer Res."},{"key":"2280_CR579","doi-asserted-by":"crossref","unstructured":"Luo, Y. et al. Long Non-coding RNAs: emerging roles in the immunosuppressive tumor microenvironment. Front. Oncol. 10, 48 (2020).","DOI":"10.3389\/fonc.2020.00048"},{"key":"2280_CR580","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.omtn.2019.05.027","volume":"17","author":"Z Yu","year":"2019","unstructured":"Yu, Z. et al. Long non-coding RNA FENDRR acts as a miR-423-5p sponge to suppress the treg-mediated immune escape of hepatocellular carcinoma cells. Mol. Ther. Nucleic Acids 17, 516\u2013529 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2280_CR581","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41388-023-02652-3","volume":"42","author":"Y Ma","year":"2023","unstructured":"Ma, Y. et al. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6\/STAT3 signaling. Oncogene 42, 1419\u20131437 (2023).","journal-title":"Oncogene"},{"key":"2280_CR582","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1331-y","volume":"18","author":"O Mar\u00edn-B\u00e9jar","year":"2017","unstructured":"Mar\u00edn-B\u00e9jar, O. et al. The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element. Genome Biol. 18, 202 (2017).","journal-title":"Genome Biol."},{"key":"2280_CR583","doi-asserted-by":"publisher","first-page":"1097694","DOI":"10.3389\/fmolb.2023.1097694","volume":"10","author":"I Bukhari","year":"2023","unstructured":"Bukhari, I. et al. Clinical implications of lncRNA LINC-PINT in cancer. Front. Mol. Biosci. 10, 1097694 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"2280_CR584","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41420-024-01997-2","volume":"10","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53\/IRF1\/type I interferon signaling axis. Cell Death Discov. 10, 240 (2024).","journal-title":"Cell Death Discov."},{"key":"2280_CR585","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/pros.23716","volume":"79","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Long non-coding RNA CCAT1\/miR-148a\/PKC\u03b6 prevents cell migration of prostate cancer by altering macrophage polarization. Prostate 79, 105\u2013112 (2019).","journal-title":"Prostate"},{"key":"2280_CR586","doi-asserted-by":"crossref","unstructured":"Fonseca-Monta\u00f1o, M. A., V\u00e1zquez-Santill\u00e1n, K. I. & Hidalgo-Miranda, A. The current advances of lncRNAs in breast cancer immunobiology research. Front. Immunol. 14, 1194300 (2023).","DOI":"10.3389\/fimmu.2023.1194300"},{"key":"2280_CR587","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-019-0400-7","volume":"20","author":"Q Hu","year":"2019","unstructured":"Hu, Q. et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat. Immunol. 20, 835\u2013851 (2019).","journal-title":"Nat. Immunol."},{"key":"2280_CR588","first-page":"1223","volume":"55","author":"PB Thomas","year":"2019","unstructured":"Thomas, P. B. et al. The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth. Int. J. Oncol. 55, 1223\u20131236 (2019).","journal-title":"Int. J. Oncol."},{"key":"2280_CR589","doi-asserted-by":"publisher","first-page":"1191913","DOI":"10.3389\/fonc.2023.1191913","volume":"13","author":"DT Zhan","year":"2023","unstructured":"Zhan, D. T. & Xian, H. C. Exploring the regulatory role of lncRNA in cancer immunity. Front. Oncol. 13, 1191913 (2023).","journal-title":"Front. Oncol."},{"key":"2280_CR590","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06152-x","volume":"9","author":"C Chen","year":"2018","unstructured":"Chen, C. et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat. Commun. 9, 3826 (2018).","journal-title":"Nat. Commun."},{"key":"2280_CR591","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52981-4","volume":"15","author":"J Ge","year":"2024","unstructured":"Ge, J. et al. Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma. Nat. Commun. 15, 8609 (2024).","journal-title":"Nat. Commun."},{"key":"2280_CR592","doi-asserted-by":"crossref","unstructured":"Chen, Y. et al. CircRNA has_circ_0069313 induced OSCC immunity escape by miR-325-3p-Foxp3 axes in both OSCC cells and Treg cells. Aging 14, 4376\u20134389 (2022).","DOI":"10.18632\/aging.204068"},{"key":"2280_CR593","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/cbin.11581","volume":"45","author":"Z Yang","year":"2021","unstructured":"Yang, Z. et al. CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR-495-3p to regulate PDL1 expression. Cell Biol. Int. 45, 1423\u20131435 (2021).","journal-title":"Cell Biol. Int."},{"key":"2280_CR594","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01398-4","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol. Cancer 20, 105 (2021).","journal-title":"Mol. Cancer"},{"key":"2280_CR595","doi-asserted-by":"crossref","unstructured":"Luo, Y.-H. et al. Circular RNA hsa_circ_0000190 facilitates the tumorigenesis and immune evasion by upregulating the expression of soluble PD-L1 in non-small-cell lung cancer. Int. J. Mol. Sci. 23, 64 (2022).","DOI":"10.3390\/ijms23010064"},{"key":"2280_CR596","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-020-01648-1","volume":"39","author":"W Hong","year":"2020","unstructured":"Hong, W. et al. Circular RNA circ-CPA4\/ let-7 miRNA\/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J. Exp. Clin. Cancer Res. 39, 149 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2280_CR597","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/jpet.121.000518","volume":"377","author":"Z Jiang","year":"2021","unstructured":"Jiang, Z. et al. circ-keratin 6c promotes malignant progression and immune evasion of colorectal cancer through microRNA-485-3p\/programmed cell death receptor ligand 1 axis. J. Pharmacol. Exp. Ther. 377, 358\u2013367 (2021).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2280_CR598","doi-asserted-by":"publisher","first-page":"2003376","DOI":"10.1002\/advs.202003376","volume":"8","author":"L Jia","year":"2021","unstructured":"Jia, L., Wang, Y. & Wang, C.-Y. circFAT1 promotes cancer stemness and immune evasion by promoting STAT3 activation. Adv. Sci. 8, 2003376 (2021).","journal-title":"Adv. Sci."},{"key":"2280_CR599","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01191-9","volume":"19","author":"C-Y Wei","year":"2020","unstructured":"Wei, C.-Y. et al. Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p\/CXCL12 axis in melanoma. Mol. Cancer 19, 84 (2020).","journal-title":"Mol. Cancer"},{"key":"2280_CR600","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00262-022-03235-z","volume":"72","author":"J Lei","year":"2023","unstructured":"Lei, J. et al. Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1\/PD-L1 checkpoint. Cancer Immunol. Immunother. 72, 101\u2013124 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"2280_CR601","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s10528-023-10493-8","volume":"62","author":"W Lu","year":"2024","unstructured":"Lu, W. et al. Circular RNA circ_0101675 promotes NSCLC cell proliferation, migration, invasion, angiogenesis and immune evasion by sponging miR-607\/PDL1 Axis. Biochem. Genet. 62, 1539\u20131555 (2024).","journal-title":"Biochem. Genet."},{"key":"2280_CR602","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110095","volume":"86","author":"Y-J Xu","year":"2021","unstructured":"Xu, Y.-J. et al. Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497\/PD-L1 pathway. Cell Signal 86, 110095 (2021).","journal-title":"Cell Signal"},{"key":"2280_CR603","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10528-022-10273-w","volume":"61","author":"R Ye","year":"2023","unstructured":"Ye, R. et al. CircSOD2 contributes to tumor progression, immune evasion and anti-PD-1 resistance in hepatocellular carcinoma by targeting miR-497-5p\/ANXA11 Axis. Biochem. Genet. 61, 597\u2013614 (2023).","journal-title":"Biochem. Genet."},{"key":"2280_CR604","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/08916934.2021.2001801","volume":"55","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. Circ-METTL15 contributes to the proliferation, metastasis, immune escape and restrains apoptosis in lung cancer by regulating miR-1299\/PDL1 axis. Autoimmunity 55, 8\u201320 (2022).","journal-title":"Autoimmunity"},{"key":"2280_CR605","doi-asserted-by":"crossref","unstructured":"Peng, W. et al. Silencing of circCRIM1 drives IGF2BP1-mediated NSCLC immune evasion. Cells 12, 273 (2023).","DOI":"10.3390\/cells12020273"},{"key":"2280_CR606","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-20-4321","volume":"81","author":"J Ge","year":"2021","unstructured":"Ge, J. et al. Epstein\u2013Barr virus\u2013encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res. 81, 5074\u20135088 (2021).","journal-title":"Cancer Res."},{"key":"2280_CR607","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1166\/sam.2023.4470","volume":"15","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Exploring the role of circular RNA (Circ_0001806) in non-small cell lung cancer progression and immune evasion through miRNA regulation. Sci. Adv. Mater. 15, 475\u2013483 (2023).","journal-title":"Sci. Adv. Mater."},{"key":"2280_CR608","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32311-2","volume":"13","author":"J Zhong","year":"2022","unstructured":"Zhong, J. et al. Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. Nat. Commun. 13, 4795 (2022).","journal-title":"Nat. Commun."},{"key":"2280_CR609","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110887","volume":"124","author":"J Zang","year":"2023","unstructured":"Zang, J. et al. Hsa_circ_0001479 accelerates tumorigenesis of gastric cancer and mediates immune escape. Int. Immunopharmacol. 124, 110887 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2280_CR610","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/15384101.2023.2225923","volume":"22","author":"C Zhang","year":"2023","unstructured":"Zhang, C. et al. Circular RNA PGPEP1 induces colorectal cancer malignancy and immune escape. Cell Cycle 22, 1743\u20131758 (2023).","journal-title":"Cell Cycle"},{"key":"2280_CR611","doi-asserted-by":"crossref","unstructured":"Lin, L. et al. Circ_0058058 drives the malignant phenotypes and immune evasion of pancreatic cancer by the MicroRNA-557\u2013dependent regulation of PDL1. Pancreas 51, 1444\u20131454 (2022).","DOI":"10.1097\/MPA.0000000000002205"},{"key":"2280_CR612","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.gendis.2022.05.005","volume":"10","author":"X Zhong","year":"2023","unstructured":"Zhong, X. et al. Circular RNA circEIF3C promotes intrahepatic cholangiocarcinoma progression and immune evasion via the miR-34a-5p\/B7-H4 axis. Genes Dis. 10, 370\u2013372 (2023).","journal-title":"Genes Dis."},{"key":"2280_CR613","doi-asserted-by":"crossref","unstructured":"Dong, L. F. et al. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622\/CMTM6 axis to promote triple-negative breast cancer and immune escape. J. Immunother. Cancer. 11, e005461 (2023).","DOI":"10.1136\/jitc-2022-005461"},{"key":"2280_CR614","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05498-9","volume":"22","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. CircRHBDD1 promotes immune escape via IGF2BP2\/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer. J. Transl. Med. 22, 704 (2024).","journal-title":"J. Transl. Med."},{"key":"2280_CR615","doi-asserted-by":"crossref","unstructured":"Zhang, N., Fan, J. & Deng, Z. CircFOXK2 enhances tumorigenesis and immune evasion in non\u2013small cell lung cancer by miR-485-5p\/PD-L1 axis. Anti-Cancer Drugs. 33, 437\u2013447 (2022).","DOI":"10.1097\/CAD.0000000000001287"},{"key":"2280_CR616","doi-asserted-by":"publisher","DOI":"10.1016\/j.bspc.2023.104960","volume":"85","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Exosomal circ-CTNNB1 derived from colorectal cancer cells induces N2 polarization of neutrophils to promote colorectal cancer cell growth and immune escape. Biomed. Signal Process Control 85, 104960 (2023).","journal-title":"Biomed. Signal Process Control"},{"key":"2280_CR617","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s12033-023-01040-2","volume":"66","author":"D Yin","year":"2024","unstructured":"Yin, D. et al. Circ_0007422 knockdown inhibits tumor property and immune escape of colorectal cancer by decreasing PDL1expression in a miR-1256-dependent manner. Mol. Biotechnol. 66, 2606\u20132619 (2024).","journal-title":"Mol. Biotechnol."},{"key":"2280_CR618","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44779-1","volume":"15","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death. Nat. Commun. 15, 499 (2024).","journal-title":"Nat. Commun."},{"key":"2280_CR619","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s11011-024-01345-4","volume":"39","author":"K Chen","year":"2024","unstructured":"Chen, K. et al. Hsa_circ_0004872 mitigates proliferation, metastasis and immune escape of meningioma cells by suppressing PD-L1. Metab. Brain Dis. 39, 895\u2013907 (2024).","journal-title":"Metab. Brain Dis."},{"key":"2280_CR620","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134\u20134140 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2280_CR621","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/ATVBAHA.120.312919","volume":"40","author":"K Yada","year":"2020","unstructured":"Yada, K. & Nogami, K. Novel insights and new developments regarding coagulation revealed by studies of the anti-factor IXa (activated factor IX)\/factor X bispecific antibody, emicizumab. Arterioscler. Thromb. Vasc. Biol. 40, 1148\u20131154 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2280_CR622","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","volume":"117","author":"T Kitazawa","year":"2017","unstructured":"Kitazawa, T. et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb. Haemost. 117, 1348\u20131357 (2017).","journal-title":"Thromb. Haemost."},{"key":"2280_CR623","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1182\/blood-2019-126670","volume":"134","author":"MS Topp","year":"2019","unstructured":"Topp, M. S. et al. A phase 2 study of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody (Ab), in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood 134, 4007 (2019).","journal-title":"Blood"},{"key":"2280_CR624","doi-asserted-by":"crossref","unstructured":"Brownstein, C. M. et al. First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+ B-cell malignancies previously treated with anti-CD20 therapy. J. Clin. Oncol. TPS3089-TPS3089 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.tps3089"},{"key":"2280_CR625","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","volume":"23","author":"L Liu","year":"2017","unstructured":"Liu, L. et al. MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin. Cancer Res. 23, 1506\u20131518 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR626","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1182\/blood.V124.21.1775.1775","volume":"124","author":"L Liu","year":"2014","unstructured":"Liu, L. et al. MGD011, humanized CD19 x CD3 DART\u00ae protein with enhanced pharmacokinetic properties, demonstrates potent T-cell mediated anti-tumor activity in preclinical models and durable B-cell depletion in cynomolgus monkeys following once-a-week dosing. Blood 124, 1775 (2014).","journal-title":"Blood"},{"key":"2280_CR627","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00280-015-2728-5","volume":"75","author":"M Mau-S\u00f8rensen","year":"2015","unstructured":"Mau-S\u00f8rensen, M. et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother. Pharmacol. 75, 1065\u20131073 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2280_CR628","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39, 1959\u20131970 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2280_CR629","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","volume":"11","author":"M Friedrich","year":"2012","unstructured":"Friedrich, M. et al. Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol. Cancer Ther.11, 2664\u20132673 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2280_CR630","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1538-7445.AM2012-3526","volume":"72","author":"M Friedrich","year":"2012","unstructured":"Friedrich, M. et al. Subcutaneous administration of PSMA\/CD3-bispecific BiTE antibody MT112\/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice. Cancer Res. 72, 3526\u20133526 (2012).","journal-title":"Cancer Res."},{"key":"2280_CR631","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","volume":"27","author":"LN Kerbauy","year":"2021","unstructured":"Kerbauy, L. N. et al. Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood\u2013derived NK cells facilitates CAR-like responses against CD30+ malignancies. Clin. Cancer Res. 27, 3744\u20133756 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR632","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe, A. et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125, 4024\u20134031 (2015).","journal-title":"Blood"},{"key":"2280_CR633","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan, Y. et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci. Transl. Med. 10, eaan5488 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2280_CR634","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss, J. et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors. Clin. Cancer Res. 24, 1287\u20131295 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2280_CR635","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood-2019-123933","volume":"134","author":"G Hernandez","year":"2019","unstructured":"Hernandez, G. et al. Pharmacodynamic effects and immune correlates of response to the CD20\/CD3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma. Blood 134, 1585 (2019).","journal-title":"Blood"},{"key":"2280_CR636","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-136295","volume":"136","author":"TJ Phillips","year":"2020","unstructured":"Phillips, T. J. et al. Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood 136, 37\u201338 (2020).","journal-title":"Blood"},{"key":"2280_CR637","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CJI.0000000000000267","volume":"42","author":"J Duell","year":"2019","unstructured":"Duell, J. et al. Functionally defective T cells after chemotherapy of B-cell malignancies can be activated by the tetravalent bispecific CD19\/CD3 antibody AFM11. J. Immunother. 42, 180\u2013188 (2019).","journal-title":"J. Immunother."},{"key":"2280_CR638","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1182\/blood.V122.21.4405.4405","volume":"122","author":"E Zhukovsky","year":"2013","unstructured":"Zhukovsky, E. et al. A CD19\/CD3 bispecific Tandab, AFM11, recruits T cells to potently and safely kill CD19+ tumor cells. Blood 122, 4405 (2013).","journal-title":"Blood"},{"key":"2280_CR639","doi-asserted-by":"crossref","unstructured":"Engelberts, P. J. et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52 (2020).","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"2280_CR640","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/01.HS9.0000563484.64538.79","volume":"3","author":"I Hiemstra","year":"2019","unstructured":"Hiemstra, I. et al. PS1301 potent anti-tumor activity of DUOBODY\u00ae-CD3XCD20 in preclinical models in vitro and in vivo. HemaSphere 3, 594 (2019).","journal-title":"HemaSphere"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02280-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02280-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02280-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:42:00Z","timestamp":1757234520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02280-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":640,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2280"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02280-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have given consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"227"}}